0001615774-17-004118.txt : 20170807 0001615774-17-004118.hdr.sgml : 20170807 20170807163835 ACCESSION NUMBER: 0001615774-17-004118 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170807 DATE AS OF CHANGE: 20170807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANAVEX LIFE SCIENCES CORP. CENTRAL INDEX KEY: 0001314052 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 208365999 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37606 FILM NUMBER: 171012029 BUSINESS ADDRESS: STREET 1: 51 W 52ND STREET, STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019-6163 BUSINESS PHONE: 800-689-3939 MAIL ADDRESS: STREET 1: 51 W 52ND STREET, STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019-6163 FORMER COMPANY: FORMER CONFORMED NAME: Thrifty Printing Inc. DATE OF NAME CHANGE: 20050111 10-Q 1 s107029_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2017

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____to _____

Commission File Number: 000-51652

ANAVEX LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

	Nevada		98-0608404
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

51 West 52^nd Street, 7^th Floor, New York, NY USA 10019

(Address of principal executive offices) (Zip Code)

1-844-689-3939

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐		Accelerated filer	☒
Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

☐ Yes ☐ No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 42,172,090 shares of common stock outstanding as of August 7, 2017.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION	F-1
ITEM 1. FINANCIAL STATEMENTS	F-1
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.	3
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.	14
ITEM 4. CONTROLS AND PROCEDURES.	15
PART II – OTHER INFORMATION	15
ITEM 1. LEGAL PROCEEDINGS.	15
ITEM 1A. RISK FACTORS.	15
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.	15
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.	15
ITEM 4. MINE SAFETY DISCLOSURES	15
ITEM 5. OTHER INFORMATION.	15
ITEM 6. EXHIBITS.	16
SIGNATURES	17

PART I - FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2017

(Unaudited)

F-1

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, 2017 and September 30, 2016

	June 30, 2017			September 30, 2016
	(Unaudited)
ASSETS
Current
Cash and cash equivalents	$	24,793,424		$	9,186,814
Sales tax recoverable		8,216			79,347
Prepaid expenses		52,694			180,124
		24,854,334			9,446,285
Deposits		52,396			52,396
	$	24,906,730		$	9,498,681

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current
Accounts payable and accrued liabilities	$	1,435,498		$	3,119,993
Deferred grant income		19,073			70,532
		1,454,571			3,190,525

Commitments - Note 6

Capital stock
Authorized:
100,000,000 common shares, par value $0.001 per share
Issued and outstanding:
42,172,090 common shares (September 30, 2016 - 36,168,299)		42,173			36,169
Additional paid-in capital		109,733,970			84,290,140
Accumulated deficit		(86,323,984	)		(78,018,153	)
		23,452,159			6,308,156
	$	24,906,730		$	9,498,681

The Accompanying Notes are an Integral Part of these Condensed Consolidated Interim Financial Statements

F-2

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

for the three and nine months ended June 30, 2017 and 2016

(Unaudited)

	Three months ended June 30,						Nine months ended June 30,
	2017			2016			2017			2016
Operating expenses
General and administrative	$	1,405,026		$	1,134,845		$	3,647,224		$	5,117,591
Research and development		2,300,277			1,158,820			6,835,700			3,888,676

Total operating expenses		(3,705,303	)		(2,293,665	)		(10,482,924	)		(9,006,267	)

Other income (expenses)
Grant income		69,146			47,767			121,116			113,701
Research and development incentive income		—			—			2,022,902			571,093
Interest income, net		26,677			2,626			48,479			6,832
Gain on settlement of accounts payable		75,204			—			75,204			151,402
Financing related charges and adjustments		—			(8	)		—			(1,175	)
Foreign exchange gain (loss)		(65,932	)		8,924			(40,128	)		(37,637	)

Total other income, net		105,095			59,309			2,227,573			804,216
Net loss before provision for income taxes		(3,600,208	)		(2,234,356	)		(8,255,351	)		(8,202,051	)

Income tax expense - current		(9,877	)		(6,000	)		(50,480	)		(23,615	)

Net loss and comprehensive loss	$	(3,610,085	)	$	(2,240,356	)	$	(8,305,831	)	$	(8,225,666	)

Loss per share
Basic and diluted	$	(0.09	)	$	(0.06	)	$	(0.21	)	$	(0.24	)

Weighted average number of shares outstanding
Basic and diluted		41,509,225			35,709,686			40,344,149			34,961,838

The Accompanying Notes are an Integral Part of these Condensed Consolidated Interim Financial Statements

F-3

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

for the nine months ended June 30, 2017

(Unaudited)

	2017			2016

Cash Flows used in Operating Activities
Net loss	$	(8,305,831	)	$	(8,225,666	)
Adjustments to reconcile net loss to net cash used in operations:
Amortization and depreciation		—			746
Accretion of debt discount		—			1,175
Stock-based compensation		3,017,876			1,276,967
Gain on settlement of accounts payable		(75,204	)		(151,402	)
Unrealized foreign exchange		—			2,649
Changes in non-cash working capital balances related to operations:
Sales tax recoverable		55,967			28,887
Prepaid expenses and deposits		127,430			32,371
Accounts payable and accrued liabilities		(1,594,127	)		(294,793	)
Deferred grant income		(51,459	)		(44,490	)
Net cash used in operating activities		(6,825,348	)		(7,373,556	)

Cash Flows provided by Financing Activity
Issuance of common shares, net of share issue costs		22,431,958			1,809,620
Net cash provided by financing activity		22,431,958			1,809,620

Increase (decrease) in cash during the period		15,606,610			(5,563,936	)
Cash and cash equivalents, beginning of period		9,186,814			15,290,976
Cash and cash equivalents, end of period	$	24,793,424		$	9,727,040

The Accompanying Notes are an Integral Part of these Condensed Consolidated Interim Financial Statements

F-4

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

For the nine months ended June 30, 2017

(Unaudited)


	Common Stock
					Additional
					Paid-in			Accumulated
	Shares		Par Value		Capital			Deficit			Total

Balance, October 1, 2016	36,168,299	$	36,169	$	84,290,140		$	(78,018,153	)	$	6,308,156
Shares issued under purchase agreement
Purchase shares	5,910,939		5,911		22,426,047			—			22,431,958
Commitment shares	40,290		40		(40	)		—			—
Shares issued upon exercise of warrants - cashless	52,562		53		(53	)		—			—
Share based compensation	—		—		3,017,876			—			3,017,876
Net loss for the period	—		—		—			(8,305,831	)		(8,305,831	)
Balance, June 30, 2017	42,172,090	$	42,173	$	109,733,970		$	(86,323,984	)	$	23,452,159

The Accompanying Notes are an Integral Part of these Condensed Consolidated Interim Financial Statements

F-5

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 1

Business Description and Basis of Presentation

Business

Anavex Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases, such as Rett syndrome.

Basis of Presentation

These interim condensed consolidated financial statements have been prepared, without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in the annual financial statements in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information presented not misleading.

These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. These interim condensed financial statements should be read in conjunction with the audited financial statements included in its annual report on Form 10-K for the year ended September 30, 2016. The Company follows the same accounting policies in the preparation of interim reports.

Operating results for the nine months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2017.

Cash and cash equivalents

The Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to be cash equivalents.

Research and Development Incentive Income

The Company participates, through its subsidiary in Australia, in the Australian government’s research and development incentive program. The research and development incentive program provides a refundable tax offset to eligible companies that engage in research and development activities in Australia. The Company recognizes as other income the amount received for qualified expenses, in the period they are received.

F-6

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 1

Business Description and Basis of Presentation – cont’d

Basic and Diluted Loss per Share

Basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into shares of common stock that were outstanding during the period.

As of June 30, 2017, loss per share excludes 6,746,964 (September 30, 2016 – 6,008,309) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.

Note 2

Recent Accounting Pronouncements

Recent Accounting Pronouncements Adopted During the Period

In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on its financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on its financial condition, results of operations and cash flows.

In April 2015, the Financial Accounting Standards Board (FASB), issued the Accounting Standards Update 2015-03, Interest - Imputation of Interest (Subtopic 835-30) - Simplifying the Presentation of Debt Issuance Costs, that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. Upon adoption, an entity must apply the new guidance retrospectively to all prior periods presented in the financial statements. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on its financial condition, results of operations and cash flows.

F-7

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 2

Recent Accounting Pronouncements – (cont’d)

Recent Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The adoption of this standard is not expected to have a material impact for any period presented.

In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-17 “Income Taxes: Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”). ASU 2015-17 eliminates the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. The adoption of this standard is not expected to have a material impact for any period presented.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (“ASU 2016-02”). The guidance would require lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right –of use assets. The guidance is effective for annual and interim reporting periods beginning on or after December 15, 2018. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

In March 2016, the FASB issued ASC 2016-09, “Compensation – Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). These amendments are intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. These amendments are effective for the Company on October 1, 2017. Early adoption is permitted. Entities have the option to apply the amendments on either a prospective basis or a modified retrospective basis. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 reduces the existing diversity in practice in financial reporting across all industries by clarifying certain existing principles in ASC 230, Statement of Cash Flows, (“ASC 230”) including providing additional guidance on how and what an entity should consider in determining the classification of certain cash flows. In addition, in November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash (“ASU 2016-18”). ASU 2016-18 clarifies certain existing principles in ASC 230, including providing additional guidance related to transfers between cash and restricted cash and how entities present, in their statement of cash flows, the cash receipts and cash payments that directly affect the restricted cash accounts. These amendments are effective for annual and interim reporting periods beginning on or after December 15, 2017. Early adoption is permitted. The adoption of ASU 2016-15 and ASU 2016-18 will modify the Company’s current disclosures and reclassifications within the consolidated statement of cash flows but they are not expected to have a material effect on the Company’s consolidated financial statements.

F-8

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 2

Recent Accounting Pronouncements – (cont’d)

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting,” clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for the Company on a prospective basis beginning on October 1, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

Other than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Note 3

Other Income

Deferred Grant Income

On June 19, 2015, the Company was awarded grant funding in the amount of $286,455. The grant has been received in exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential treatment for Parkinson’s disease.

The grant income has been deferred and is being amortized to other income over the related commitment period as the related research and development expenditures are incurred. During the three and nine months ended June 30, 2017, the Company recognized $69,146 and $121,116, respectively (2016: $47,767 and $113,701) of this grant on its statement of operations within grant income.

Research and development tax incentive

During the three and nine months ended June 30, 2017, the Company received other income of $Nil and $2,022,902, respectively (2016: $Nil and $571,093, respectively) in respect of a research and development incentive program offered by the Australian government.

F-9

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 4

Lincoln Park Purchase Agreement

On October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the “2015 Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period. In connection with the Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park whereby the Company agreed to file registration statements with the Securities and Exchange Commission covering the shares of the Company’s common stock that may be issued to Lincoln Park under the Purchase Agreement.

The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park’s committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.

In consideration for entering into the 2015 Purchase Agreement, the Company issued to Lincoln Park 179,598 shares of common stock as a commitment fee and agreed to issue up to 89,799 shares pro rata, when and if, Lincoln Park purchases at the Company’s discretion the $50,000,000 aggregate commitment.

During the nine months ended June 30, 2017, the Company issued to Lincoln Park an aggregate of 5,951,229 shares of common stock under the Purchase Agreement, including 5,910,939 shares of common stock for an aggregate purchase price of $22,431,958 and 40,290 commitment shares. At June 30, 2017, an amount of $26,210,241 remained available under the 2015 Purchase Agreement.

Note 5

Related Party Transactions

As at June 30, 2017, included in accounts payable and accrued liabilities was $41,195 (September 30, 2016: $59,264) owing to directors and officers of the Company for director fees and reimbursable expenses, and a former director and officer of the Company for unpaid fees.

Note 6

Commitments

Lease Commitment

The Company is committed to lease payments as follows:

Fiscal year ending September 30,
2017	$	28,047
2018		112,189
2019		56,094
	$	196,330

F-10

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 6

Commitments – (cont’d)

Litigation

The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.

Share Purchase Warrants

A summary of the status of Company’s outstanding share purchase warrants is presented below:

	Number of Shares			Weighted Average Exercise Price
Balance, October 1, 2015		4,272,890		$	2.11
Exercised		(2,463,581	)	$	1.67
Balance, September 30, 2016		1,809,309		$	2.70
Exercised		(200,000	)	$	3.00
Balance,June 30, 2017		1,609,309		$	2.66

At June 30, 2017, the Company had share purchase warrants outstanding of 1,609,309, with a weighted average exercise price of $2.66 as follows:

Number		Exercise Price		Expiry Date
	1,262,180	$	3.00	July 5, 2018
	30,000	$	4.00	February 24, 2019
	277,127	$	1.20	March 13, 2019
	1,252	$	1.68	March 13, 2019
	31,250	$	1.24	May 31, 2019
	7,500	$	1.04	May 31, 2019
	1,609,309

All of the warrants expiring on July 5, 2018 contain a contingent call provision whereby the Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Company’s common stock exceeds $6.00 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements.

During the nine months ended June 30, 2017, 200,000 share purchase warrants were cashless exercised, resulting in the issuance of 52,562 shares of common stock.

F-11

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 6

Commitments – (cont’d)

Stock–based Compensation Plan

2015 Stock Option Plan

On September 18, 2015, the Company’s board of directors approved a 2015 Omnibus Incentive Plan (the “2015 Plan”), which provides for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.

The maximum number of our common shares reserved for issue under the plan is 6,050,553 shares subject to adjustment in the event of a change of the Company’s capitalization. As a result of the adoption of the 2015 Plan, no further option awards will be granted under any previously existing stock option plan. Stock option awards previously granted under previously existing stock option plans remain outstanding in accordance with their terms.

The 2015 Plan is administered by the board of directors, except that it may, in its discretion, delegate such responsibility to a committee of such board. The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.

A summary of the status of Company’s outstanding stock purchase options is presented below:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Grant Date fair value
Outstanding at October 1, 2015		1,822,500		$	2.00
Granted		2,401,500		$	5.22	$	4.38
Expired		(25,000	)	$	14.68
Outstanding at September 30, 2016		4,199,000		$	3.76
Granted		1,080,000		$	5.55	$	5.48
Forfeited		(141,345	)	$	4.02
Outstanding at June 30, 2017		5,137,655		$	4.13
Exercisable at June 30, 2017		3,124,885		$	2.89
Exercisable at September 30, 2016		2,290,717		$	2.41

F-12

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 6

Commitments – (cont’d)

Stock-based Compensation Plan – (cont’d)

At June 30, 2017, the following stock options were outstanding:


Number of Shares							Aggregate		Remaining
		Number		Exercise			Intrinsic		Contractual
Total		Vested		Price		Expiry Date	Value		Life (yrs)
	500,000		500,000	$	1.60	July 5, 2023	$	1,860,000		6.01
	75,000		75,000	$	1.20	May 7, 2024		309,000		6.85
	125,000		93,750	$	1.32	May 8, 2024		500,000		6.86
	718,750		718,750	$	0.92	April 2, 2025		3,162,500		7.76
	29,167		29,167	$	1.44	June 8, 2025		113,168		7.94
	50,000		33,333	$	1.76	June 15, 2025		178,000		7.96
	273,542		177,500	$	5.04	September 18, 2025		76,592		8.22
	1,500		1,500	$	5.64	September 30, 2025		—		8.25
	31,250		18,230	$	5.68	October 2, 2025		—		8.26
	25,000		14,583	$	8.98	October 16, 2025		—		8.30
	1,500		1,500	$	5.57	December 31, 2025		—		8.50
	1,500		1,500	$	4.90	March 31, 2026		630		8.75
	1,500		1,500	$	5.66	April 27, 2026		—		8.82
	19,697		19,697	$	4.09	May 18, 2026		24,227		8.88
	1,500		1,500	$	6.11	June 30, 2026		—		9.00
	379,625		94,906	$	6.26	July 5, 2026		—		9.01
	861,429		215,357	$	7.06	July 18, 2026		—		9.05
	40,000		13,333	$	3.06	September 7, 2026		90,400		9.19
	1,006,696		1,006,696	$	3.28	September 22, 2026		2,053,660		9.23
	89,999		29,999	$	3.63	October 3, 2026		152,098		9.26
	15,000		3,750	$	4.35	December 9, 2026		14,550		9.44
	50,000		—	$	5.39	February 7, 2027		—		9.61
	40,000		6,666	$	5.26	February 17, 2027		2,400		9.63
	800,000		66,668	$	5.92	May 12, 2027		—		9.86
	5,137,655		3,124,885				$	8,537,225

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company’s stock for the options that were in-the-money at June 30, 2017.

F-13

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2017

(Unaudited)

Note 6

Commitments – (cont’d)

Stock–based Compensation Plan – (cont’d)

The Company recognized stock based compensation expense of $1,159,716 and $3,017,876, respectively, during the three and nine months ended June 30, 2017 (2016: $230,239 and $666,967 respectively) in connection with the issuance and vesting of stock options in exchange for services, and $Nil and $Nil respectively (2016: $Nil and $610,000, respectively), in connection with the vesting of restricted stock in exchange for services. These amounts have been included in general and administrative expenses and research and development expenses on the Company’s statement of operations as follows:

	Three months ended June 30,				Nine months ended June 30,
	2017		2016		2017		2016
General and administrative	$	574,470	$	127,473	$	1,452,181	$	715,991
Research and development		585,246		102,766		1,565,695		560,976
Total share based compensation	$	1,159,716	$	230,239	$	3,017,876	$	1,276,967

An amount of approximately $8,872,029 in stock based compensation is expected to be recorded over the remaining term of such options through March 31, 2020.

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:

	2017			2016
Risk-free interest rate		1.98	%		1.67	%
Expected life of options (years)		6.82			6.63
Annualized volatility		111.67	%		105.21	%
Dividend rate		0.00	%		0.00	%

The fair value of restricted stock compensation charges during the nine months ended June 30, 2016 was determined with reference to the quoted market price of the Company’s shares on the commitment date.

Note 7

Comparative Figures

Certain comparative figures have been reclassified to conform to the current year’s presentation.

F-14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the anticipated start dates, durations and completion dates of our ongoing and future clinical studies, statements regarding the anticipated designs of our future clinical studies, statements regarding our anticipated future regulatory submissions and statements regarding our anticipated future cash position. We have based these forward-looking statements largely on our current expectations and projections about future events, including the responses we expect from the U.S. Food and Drug Administration, (“FDA”), and other regulatory authorities and financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical and clinical trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions including without limitation the risks described in “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q. These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable laws including the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.

As used in this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” and “Anavex” mean Anavex Life Sciences Corp., unless the context clearly requires otherwise.

Our Current Business

Anavex Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX^TM 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.

In November 2016, a Phase 2a clinical trial going over 52 weeks was completed for ANAVEX^TM 2-73 in mild-to-moderate Alzheimer’s patients. This open-label randomized trial met both primary and secondary endpoints, and was designed to assess the safety and exploratory efficacy of ANAVEX^TM 2-73 in 32 patients. ANAVEX^TM 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer’s disease. ANAVEX^TM 2-73 showed no serious adverse events in a previously performed Phase 1 study. In preclinical studies, ANAVEX^TM 2-73 demonstrated anti-amnesic and neuroprotective properties in various animal models including the transgenic mouse model Tg2576. In March 2016, we received approval from the Ethics Committee in Australia to extend the ongoing Phase 2a clinical trial, which had been requested by patients and their caregivers. The trial extension allows participants who completed 52 weeks in PART B to rollover into a new trial and continue taking ANAVEX^TM 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety data. The trial is independent of the Company’s planned larger Phase 2/3 double-blind, placebo-controlled study of ANAVEX^TM 2-73 in Alzheimer’s disease.

In September 2016, the Company presented positive preclinical data for ANAVEX^TM 2-73 in Parkinson’s disease, which demonstrated significant improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J Fox Foundation.

In February 2016, the Company presented positive preclinical data for ANAVEX^TM 2-73 in Rett syndrome, a rare neurodevelopmental disease indication. The study was funded by the Rettsyndrome.org foundation. In January 2017, the Company was awarded a financial grant from the Rettsyndrome.org foundation of a minimum of $0.6 million to cover the majority of a planned U.S. multicenter Phase 2 clinical trial of ANAVEX^TM 2-73 for the treatment of Rett syndrome. The Phase 2 trial is scheduled to begin in calendar 2017 and will be a randomized, double blind, placebo-controlled study of ANAVEX^TM 2-73 in patients with Rett syndrome lasting up to 12 weeks. Primary and secondary endpoints include safety as well as Rett syndrome conditions such as cognitive impairment, motor impairment, behavioral symptoms and seizure activity.

We intend to identify and initiate discussions with potential commercial partners within the next 12 months. Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.

Our Pipeline

Our research and development pipeline includes one clinical drug candidate and several compounds in different stages of pre-clinical study.

Our proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Compounds that have been subjects of our research include the following:

ANAVEX^TM2-73

ANAVEX^TM2-73 may offer a disease-modifying approach in Alzheimer’s disease (“AD”) by using ligands that activate sigma-1 receptors.

In AD animal models, ANAVEX^TM 2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX^TM 2-73 has shown a potential dual mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576, ANAVEX^TM 2-73 induced a statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also significantly alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.

Based on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (“SAD”) clinical trial of ANAVEX^TM 2-73 in 2011. In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram parameters. ANAVEX^TM 2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.

The ANAVEX^TM 2-73 Phase 1 SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers between the ages of 18 and 55 received single, ascending oral doses over the course of the trial. Study endpoints included safety and tolerability together with pharmacokinetic parameters. Pharmacokinetics includes the absorption and distribution of a drug, the rate at which a drug enters the blood and the duration of its effect, as well as chemical changes of the substance in the body. This study was conducted in Germany in collaboration with ABX-CRO, a clinical research organization and the Technical University of Dresden.

In December 2014, a Phase 2a clinical trial was initiated for ANAVEX 2-73^TM, which is being evaluated for the treatment of Alzheimer’s disease. The open-label randomized trial is designed to assess the safety and exploratory efficacy of ANAVEX^TM2-73 in 32 patients with mild to moderate Alzheimer’s disease. ANAVEX^TM 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer’s disease. ANAVEX^TM 2-73 showed no serious adverse events in a previously performed Phase 1 study. In pre-clinical studies ANAVEX^TM 2-73 demonstrated anti-amnesic and neuroprotective properties in various animal models including the transgenic mouse model Tg2576.

The Phase 2a study met both primary and secondary objectives of the study. The 31-week preliminary exploratory safety and efficacy data from the Phase 2a study of ANAVEX^TM 2-73 in Alzheimer’s patients, with most also receiving donepezil, the current standard of care, demonstrated favorable safety, maximum tolerated dose, positive dose response, sustained efficacy response through 31 weeks for both cognitive and functional measures, as well as positive unexpected therapeutic response events. ANAVEX^TM2-73 continued to demonstrate a favorable adverse event profile through 31 weeks in a patient population of elderly Alzheimer’s patients with varying degrees of physical fragility. The most common side effects across all adverse events categories tended to be of mild severity grade 1, and were resolved with dose reductions that were anticipated within the adaptive design of the study protocol.

At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEX^TM 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures. This data of stabilization is promising since Alzheimer’s disease is a progressive disease where current therapeutics are only able to temporarily slow the worsening of dementia symptoms and do not stop the disease from progressing. At 41 weeks, oral daily dosing between 10mg and 50mg, ANAVEX^TM2-73 was well tolerated, and no patients discontinued treatment due to adverse events. There were no clinically significant treatment-related adverse events, and no serious adverse events.

Pre-specified exploratory analyses included the cognitive (MMSE) and the functional (ADCS-ADL) changes from baseline. A continued stabilization of both cognitive (MMSE) and functional (ADCS-ADL) measures in patients treated with ANAVEX^TM 2-73 was observed. This correlation was positive with all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP).

At 57 weeks, Alzheimer’s patients taking a daily oral dose between 10mg and 50mg, ANAVEX^TM 2-73 was well tolerated. There were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized dosing of ANAVEX^TM 2-73 throughout the 57-week study, continued significant improvements from baseline of cognitive, functional and behavioural scores in a group of patients were observed, respectively. This data will be analyzed using refined mathematical modeling methods in conjunction with the detailed pharmacokinetic (PK) information.

ANAVEX^TM2-73 data presented meets prerequisite information in order to progress into a Phase 2/3 placebo controlled study, which is currently in the preparation phase.

Preclinical data also validates ANAVEX^TM 2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer’s as well as neurodevelopmental diseases, more specifically, Parkinson’s disease, epilepsy, Rett syndrome, Angelman syndrome and Fragile X syndrome.

For Parkinson’s disease, data demonstrates significant improvements and restoration of function in a classic animal model of Parkinson’s disease. Significant improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints.

For epilepsy, data demonstrates both significant and dose related improvement in the reduction of seizures, as well as significant synergy with each of three generations of epilepsy drugs currently on the market.

In Rett syndrome, a rare neurodevelopmental disease indication, administration of ANAVEX^TM 2-73 resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX^TM 2-73 was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX^TM 2-73 for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome disease mouse.

The Company is currently in preparation for a Phase 2 clinical trial for the treatment of Rett syndrome.

In May 2017, the Company announced new preclinical data for ANAVEX^TM 2-73 in the neurodevelopmental disorders Angelman syndrome and Fragile X syndrome. For Angelman syndrome, in a study sponsored by the Foundation for Angelman Syndrome, ANAVEX^TM2-73 was assessed in a mouse model for the development of audiogenic seizures. The results indicated that ANAVEX^TM2-73 administration significantly reduced audiogenic-induced seizures. In Fragile X, in a recent study sponsored by Fraxa Research Foundation, data demonstrated that ANAVEX^TM 2-73 restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX^TM 2-73 normalization of BDNF expression could be a contributing factor for the positive data observed in both neurodevelopmental and neurodegenerative disorders.

Recent preclinical data presented also indicates that ANAVEX^TM 2-73 demonstrates protective effects of the mitochondrial enzyme complexes I and IV during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases. The FDA has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of Rett syndrome and infantile spasms, in May 2016 and June 2016, respectively.

ANAVEX 3-71

ANAVEX 3-71, previously named AF710B is a preclinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has been shown to enhance neuroprotection and cognition in Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications. It is highly effective in very small doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX 3-71 indicates extensive therapeutic advantages in Alzheimer’s and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.

A recent preclinical study examined the response of ANAVEX 3-71 in aged transgenic animal models, and showed a significant reduction in rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016, the FDA granted Orphan Drug Designation to ANAVEX 3-71 for the treatment of Frontotemporal dementia.

In April 2017, new preclinical data was presented for ANAVEX 3-71 indicating that during pathological conditions, ANAVEX 3-71 demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes. In neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, synaptogenesis is believed to be impaired. Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX 3-71 demonstrates protective effects of the mitochondrial enzyme complexes I and IV during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

ANAVEX 1-41

ANAVEX 1-41 is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and destroys cells and is believed by some scientists to be a primary cause of AD. In addition, in animal models, ANAVEX 1-41 prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.

Recent preclinical data presented also indicates that ANAVEX 1-41 demonstrates protective effects of the mitochondrial enzyme complexes I and IV during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

ANAVEX 1037

ANAVEX 1037 is designed for the treatment of prostate cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical studies, this compound revealed antitumor potential with no toxic side effects. It has also been shown to selectively kill human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications describe sigma receptor ligands positively, highlighting the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.

ANAVEX 1066

ANAVEX 1066, a mixed sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic pain and visceral pain. ANAVEX 1066 was tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model of neuropathic pain, a single oral administration of ANAVEX 1066 dose dependently restored the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX 1066 returned the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX 1066 and a favorable safety profile in a battery of behavioral measures.

Our compounds are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown in human testing.

Our Target Indications

We have developed compounds with potential application to two broad categories and several specific indications. The two categories are diseases of the central nervous system, and cancer. Specific indications include:

●	Alzheimer’s disease - In 2016, an estimated 5.4 million Americans were suffering from Alzheimer’s disease. The Alzheimer’s Association® reports that by 2025, 7.1 million Americans will be afflicted by the disease, a 30 percent increase from currently affected patients. Medications on the market today treat only the symptoms of Alzheimer’s disease and do not have the ability to stop its onset or its progression. There is an urgent and unmet need for both a disease modifying cure for Alzheimer’s disease as well as for better symptomatic treatments.

●	Parkinson’s disease – Parkinson’s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson’s disease afflicts more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson’s disease market is set to expand from $2.1 billion in 2014 to $3.2 billion by 2021, according to business intelligence provider GBI Research.

●	Rett syndrome - Rett syndrome is a rare non-inherited genetic postnatal progressive neurodevelopmental disorder that occurs almost exclusively in girls and leads to severe impairments, affecting nearly every aspect of the child’s life: their ability to speak, walk, eat, and even breathe easily. Rett syndrome is caused by mutations in the MECP2 gene and strikes all racial and ethnic groups and occurs worldwide in approximately 1 in every 10,000-15,000 live female births.

●	Depression - Depression is a major cause of morbidity worldwide according to the World Health Organization. Pharmaceutical treatment for depression is dominated by blockbuster brands, with the leading nine brands accounting for approximately 75% of total sales. However, the dominance of the leading brands is waning, largely due to the effects of patent expiration and generic competition.

●	Epilepsy - Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, epilepsy affects 2.2 million Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs. GBI Research estimates that the epilepsy market will increase to $4.5 billion by 2019.

●	Neuropathic Pain – We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.

●	Malignant Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide malignant melanoma market is expected to grow to $4.4 billion by 2022.

●	Prostate Cancer – Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase to nearly $18.6 billion in 2017 according to BCC Research.

●	Pancreatic Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 45,000 new cases of pancreatic cancer will be diagnosed this year and approximately 38,000 patients will die as a result of their cancer. Sales predictions by GBI Research forecast that the market for the pharmaceutical treatment of pancreatic cancer in the United States and five largest European countries will increase to $2.9 billion by 2021.

Financial Highlights

We had cash of $24.8 million at June 30, 2017, compared to $9.2 million at September 30, 2016. The increase in cash is primarily a result of the sale of shares of common stock for aggregate proceeds of $22.4 million under a Purchase Agreement by and between the Company and Lincoln Park Capital Fund, LLC (“Lincoln Park”) dated October 21, 2015 (the “Purchase Agreement”). During the fiscal year to the end of our third quarter, we also received $2.0 million in other income from the Australian Tax Office, as part of a government sponsored research and development incentive program.

Operating expenses for the third quarter of fiscal 2017 were $3.7 million, compared to $2.3 million for the comparable quarter in fiscal 2016. The principal reason for the increase in operating costs was due to an increase in research and development costs, as a result of increased preclinical activities, as well as clinical preparatory activities and the ongoing Phase 2a clinical trial extension.

We expect our research and development expenses will continue to increase as we proceed into a Phase 2/3 clinical study for Alzheimer’s disease, a Phase 2 trial for Rett syndrome, a Phase 2 study in Parkinson’s disease and continue to advance other auxiliary research and development activities. We continue to target potential research partners to further advance our pipeline compounds.

Net loss for the third quarter of fiscal 2017 was $3.6 million, or $0.09 per share, as compared to $2.2 million, or $0.06 per share in the comparable quarter in fiscal 2016.

Results of Operations

Revenue

We have not earned any revenues since our inception on January 23, 2004. We do not anticipate earning any revenues until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.

Three months ended June 30, 2017 compared to three months ended June 30, 2016

Operating Expenses

Our operating expenses for the three months ended June 30, 2017 were $3.7 million which represents an increase of $1.4 million from the comparable quarter in fiscal 2016. The increase in operating costs was primarily attributable to an increase in research and development expenses of $1.1 million, primarily as a result of an increase in preclinical programs on ANAVEX^TM 2-73 for additional indications, as well as clinical trial preparatory activities, and an expanded research and development team.

There was also an increase in general and administrative expenses of $0.3 million, which is mostly related to an increase in salaries and wages, as a result of an increase in staff.

Other income (expenses)

The net amount of other income for the quarter ended June 30, 2017 was $0.1 million as compared to $0.06 million for the comparable quarter ended June 30, 2016. The largest reason for the increase in other income was a gain in respect of a negotiated settlement of accounts payable.

Nine months ended June 30, 2017 compared to nine months ended June 30, 2016

Operating Expenses

Our operating expenses for the nine months ended June 30, 2017 were $10.5 million which represents an increase of $1.5 million from the comparable period in fiscal 2016. The increase in operating costs was primarily attributable to an increase in research and development expenses of $2.9 million, attributable to expanded preclinical programs, clinical preparatory activities and an expanded research and development team. The increase in research and development expenses was substantially offset by a decrease in general and administrative expenses related to one-time charges incurred in the comparable period and increased legal fees in the comparable period as a result of financing and related activities in that period.

Other income (expenses)

The net amount of other income for the nine months ended June 30, 2017 was $2.2 million as compared to $0.8 million for the nine months ended June 30, 2016. The largest reason for the increase in other income was the receipt of $2.0 million in other income as part of a research and development incentive program offered by the Australian Tax Office, which was granted in connection with eligible expenditures from our clinical trials in Australia.

Liquidity and Capital Resources

Working Capital

	June 30, 2017		September 30, 2016
Current Assets	$	24,854,334	$	9,446,285
Current Liabilities		1,454,571		3,190,525
Working Capital	$	23,399,763	$	6,255,760

At June 30, 2017, we had $24.8 million in cash, an increase of $15.6 million from September 30, 2016. The principal reason for this increase is the $22.4 million in cash received from the issuance of shares of common stock under the Purchase Agreement. In our second quarter, we also received approximately $2.0 million in other income as part of a research and development incentive program offered by the Australian Tax Office. We intend to use the majority of our capital resources to complete the next clinical trials for ANAVEX^TM 2-73, and to perform work necessary to prepare for further clinical development.

Cash Flows

	Nine months ended June 30,
	2017			2016
Cash flows used in operating activities	$	(6,825,348	)	$	(7,373,556	)
Cash flows from financing activities		22,431,958			1,809,620
Increase (decrease) in cash during the period	$	15,606,610		$	(5,563,936	)

Cash flow used in operating activities

Cash used in operating activities for the nine-month period ended June 30, 2017 was $6.8 million, compared to $7.4 million during the nine-month period ended June 30, 2016. The principal reason for this decrease in cash used from operating activities in the current period is the receipt of $2.0 million in research and development incentive income during our second quarter, compared to $0.6 million in the comparable nine-month period.

Cash flow provided by financing activities

Cash provided by financing activities for the period ended June 30, 2017 was $22.4 million, attributable to cash received from the issuance of 5,951,229 common shares at various market prices under the Purchase Agreement.

In the comparable period ended June 30, 2016, cash provided by financing activities amounted to $1.8 million, mostly attributable to cash received pursuant to the exercise of outstanding share purchase warrants, and cash received from the issuance of common shares under a purchase agreement with Lincoln Park dated July 5, 2013, which is no longer in effect.

Other Financing

On October 21, 2015, we entered into the Purchase Agreement) with Lincoln Park, pursuant to which Lincoln Park committed to purchase up to $50.0 million of our common stock. Concurrently with the execution of the Purchase Agreement, we issued 179,598 shares of our common stock to Lincoln Park as a fee for its commitment to purchase shares of our common stock under the Purchase Agreement. The shares that may be sold pursuant to the Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a 36-month period ending September 6, 2019, the date the Securities and Exchange Commission (the “SEC”) declared effective the related registration statement. As of June 30, 2017, an amount of $26.2 million remained available under the Purchase Agreement.

We may direct Lincoln Park, at our sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of our common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park’s committed obligation under any single purchase shall not exceed $2.0 million. The purchase price of shares of common stock related to the financing are based on the then prevailing market prices of such shares at the time of sales, as described in the Purchase Agreement.

Other than our rights related to the Lincoln Park financing, there can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale down some or all of our research and development activities or perhaps even cease the operation of our business.

We expect that we will be able to continue to fund our operations through the next 12 months using existing cash on hand, the sale of shares of common stock under the Purchase Agreement, and through other equity financing in the future. If we raise additional financing by issuing equity securities, our existing stockholders’ ownership will be diluted. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

Contractual Obligations

The following table summarizes our contractual obligations as of June 30, 2017, excluding amounts related to uncertain tax positions, funding commitments, contingent development, and regulatory and commercial milestone payments:

Contractual Obligations	Payments Due by Period
	Total		Less than 1 year		1-3 years		4 - 5 years		After 5 years
Long-Term Debt	—		—		—		—		—
Capital Lease Obligations	—		—		—		—		—
Operating Leases	$	196,330	$	112,189	$	84,141		—		—
Unconditional Purchase Obligations		—		—		—		—		—
Other Long-Term Obligations		—		—		—		—		—
Total Contractual Cash Obligations	$	196,330	$	112,189	$	84,141		—		—

Application of Critical Accounting Policies

Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

We base our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due to changes in circumstances, weather, politics, global economics, mechanical problems, general business conditions and other factors. Our significant estimates are related to the valuation of warrants and options.

There are accounting policies that we believe are significant to the presentation of our financial statements. The most significant of these accounting policies relates to the accounting for our research and development expenses and stock-based compensation expense and derivative liabilities.

Research and Development Expenses

Research and developments costs are expensed as incurred. These expenses are comprised of the costs of our proprietary research and development efforts, including salaries, facilities costs, overhead costs and other related expenses as well as costs incurred in connection with third-party collaboration efforts. Milestone payments made by us to third parties are expensed when the specific milestone has been achieved.

In addition, we incur expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability of success and length of time to developing commercial applications of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties, we expense the acquisition of patents and trademarks.

Stock-based Compensation

We account for all stock-based payments and awards under the fair value based method.

Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if we had paid cash instead of paying with or using equity based instruments. The cost of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.

We account for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with a corresponding increase to additional capital surplus. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in additional capital surplus, is recorded as an increase to share capital.

We use the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in assumptions can materially affect the fair value estimate and therefore the Black-Scholes model does not necessarily provide a reliable single measure of the fair value of our share purchase options.

Recent Accounting Pronouncements

In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on our financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on our financial condition, results of operations and cash flows.

In April 2015, the Financial Accounting Standards Board (FASB), issued the Accounting Standards Update 2015-03, Interest - Imputation of Interest (Subtopic 835-30) - Simplifying the Presentation of Debt Issuance Costs, that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. Upon adoption, an entity must apply the new guidance retrospectively to all prior periods presented in the financial statements. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on our financial condition, results of operations and cash flows.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (“ASU 2016-02”). The guidance would require lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right –of use assets. The guidance is effective for annual and interim reporting periods beginning on or after December 15, 2018. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In March 2016, the FASB issued ASC 2016-09, “Compensation – Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). These amendments are intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. These amendments are effective for annual and interim reporting periods beginning on or after December 15, 2016. Early adoption is permitted. Entities have the option to apply the amendments on either a prospective basis or a modified retrospective basis. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 reduces the existing diversity in practice in financial reporting across all industries by clarifying certain existing principles in ASC 230, Statement of Cash Flows, (“ASC 230”) including providing additional guidance on how and what an entity should consider in determining the classification of certain cash flows. In addition, in November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash (“ASU 2016-18”). ASU 2016-18 clarifies certain existing principles in ASC 230, including providing additional guidance related to transfers between cash and restricted cash and how entities present, in their statement of cash flows, the cash receipts and cash payments that directly affect the restricted cash accounts. These amendments are effective for annual and interim reporting periods beginning on or after December 15, 2017. Early adoption is permitted. The adoption of ASU 2016-15 and ASU 2016-18 will modify the Company’s current disclosures and reclassifications within the consolidated statement of cash flows but is not expected to have a material effect on the our consolidated financial statements.

Other than noted above, we do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Item 3. Quantitative and Qualitative Disclosures about Market Risks.

We are exposed to a variety of market risks, including interest rate risk, foreign currency exchange risk and equity price risk.

Interest Rate Risk

We invest a major portion of our cash surplus in bank deposits in the United States and, to a lesser extent, Australia. Since the bank deposits typically carry fixed interest rates, financial income over the holding period is not sensitive to changes in interest rates, but only the fair value of these instruments. However, our interest gains from future deposits could decline in the future as a result of changes in the financial markets. In any event, given the historic low levels of interest rates, we estimate that a decline in the interest rates we are currently receiving will not result in a material adverse effect to our business.

Foreign Currency Exchange Risk

A significant portion of our expenditures, including clinical research expenses relate to our operations in Australia and a portion of our consultancy expenses are incurred in Euros. The cost of those expenses, as expressed in US dollars, is influenced by the exchange rate of these currencies against the US Dollar. If the US dollar declines in value in relation to these currencies, it will become more expensive for us to fund our operations; however, we estimate that a decline in the US Dollar will not result in a material adverse effect to our business because, to limit this risk, the Company holds minimal cash reserves in currencies other than the US Dollar.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive officer and our principal financial officer, to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective, as of June 30, 2017.

Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2017, there were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a15(d) or 15d15(d) of the Exchange Act during the period covered by this Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

We know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse party or has a material interest adverse to our or our subsidiary’s interest.

Item 1A. Risk Factors.

In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in “Item 1A – Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016 filed with the SEC on December 14, 2016. These risks could materially and adversely affect our business, financial condition and results of operations. The risks described in our Form 10-K have not changed materially; however, they are not the only risks we face. Our operations could also be affected by additional factors that are not presently known to us or by factors that we currently consider immaterial to our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the period covered by this Quarterly Report on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously reported in a Current Report on Form 8-K.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Number	Description
(3)	Articles of Incorporation and Bylaws
3.1	Articles of Incorporation (incorporated by reference to an exhibit to our Registration Statement on Form SB-2 filed on January 13, 2005)
3.2	Bylaws (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on September 28, 2007)
3.3	Articles of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on January 25, 2007)
3.4	Certificate of Amendment to the Articles of Incorporation (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on March 30, 2015)
3.5	Certificate of Change to the Articles of Incorporation (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on October 6, 2015)
(4)	Instruments defining rights of security holders, including indentures
4.1	Specimen Stock Certificate (incorporated by reference to an exhibit to our Registration Statement on Form SB-2 filed on January 13, 2005)
(31)	Rule 13a-14(a)/15(d)-14(a)Certifications
31.1*	Certification of Christopher Missling, PhD.
31.2*	Certification of Sandra Boenisch
(32)	Section 1350 Certifications
32.1*	Certification of Christopher Missling, PhD and Sandra Boenisch.
(101)	XBRL
101.INS*	XBRL INSTANCE DOCUMENT
101.SCH*	XBRL TAXONOMY EXTENSION SCHEMA
101.CAL*	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF*	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB*	XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE*	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ANAVEX LIFE SCIENCES CORP.


/s/Christopher Missling, PhD

Christopher Missling, PhD
Chief Executive Officer
(Principal Executive Officer)
Date: August 7, 2017

/s/Sandra Boenisch

Sandra Boenisch, CPA, CGA
Principal Financial Officer
(Principal Financial and Accounting Officer)
Date: August 7, 2017

EX-31.1 2 s107029_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Christopher Missling, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended June 30, 2017 of Anavex Life Sciences Corp. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2017

/s/Christopher Missling, PhD
Christopher Missling, PhD
Chief Executive Officer, President and Secretary
(Principal Executive Officer)

EX-31.2 3 s107029_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Sandra Boenisch, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended June 30, 2017 of Anavex Life Sciences Corp. (the “registrant”);

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2017

/s/Sandra Boenisch
Sandra Boenisch, CPA, CGA
Principal Financial Officer, Treasurer
(Principal Financial and Accounting Officer)

EX-32.1 4 s107029_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Anavex Life Sciences Corp. (the “Company”) on Form 10-Q for the three months ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 7, 2017	/s/Christopher Missling, PhD
	Christopher Missling, PhD
	Chief Executive Officer, President, Secretary
	(Principal Executive Officer)
	/s/Sandra Boenisch
	Sandra Boenisch, CPA, CGA
	Principal Financial Officer, Treasurer
	(Principal Financial and Accounting Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 avxl-20170630.xml XBRL INSTANCE FILE 0001314052 2016-10-01 2017-06-30 0001314052 2015-10-01 2016-09-30 0001314052 2017-04-01 2017-06-30 0001314052 2016-04-01 2016-06-30 0001314052 2015-10-01 2016-06-30 0001314052 2015-06-18 2015-06-19 0001314052 avxl:ResearchAndDevelopmentIncentiveProgramMember 2017-04-01 2017-06-30 0001314052 avxl:ResearchAndDevelopmentIncentiveProgramMember 2016-10-01 2017-06-30 0001314052 avxl:ResearchAndDevelopmentIncentiveProgramMember 2016-04-01 2016-06-30 0001314052 avxl:ResearchAndDevelopmentIncentiveProgramMember 2015-10-01 2016-06-30 0001314052 avxl:PurchaseAgreementMember avxl:LincolnParkCapitalFundLLCMember 2015-10-19 2015-10-21 0001314052 avxl:PurchaseAgreementMember avxl:LincolnParkCapitalFundLLCMember 2016-10-01 2017-06-30 0001314052 us-gaap:ManagementMember 2017-06-30 0001314052 us-gaap:ManagementMember 2016-09-30 0001314052 2017-06-30 0001314052 avxl:PurchaseWarrantsMember 2015-10-01 2016-09-30 0001314052 avxl:PurchaseWarrantsMember 2015-09-30 0001314052 avxl:PurchaseWarrantsMember 2016-09-30 0001314052 avxl:PurchaseWarrantsMember 2016-10-01 2017-06-30 0001314052 avxl:PurchaseWarrantsMember 2017-06-30 0001314052 avxl:PurchaseWarrants1Member 2016-10-01 2017-06-30 0001314052 avxl:PurchaseWarrants2Member 2016-10-01 2017-06-30 0001314052 avxl:PurchaseWarrants3Member 2016-10-01 2017-06-30 0001314052 avxl:PurchaseWarrants4Member 2016-10-01 2017-06-30 0001314052 avxl:PurchaseWarrants5Member 2016-10-01 2017-06-30 0001314052 avxl:PurchaseWarrants6Member 2016-10-01 2017-06-30 0001314052 avxl:PurchaseWarrants1Member 2017-06-30 0001314052 avxl:PurchaseWarrants2Member 2017-06-30 0001314052 avxl:PurchaseWarrants3Member 2017-06-30 0001314052 avxl:PurchaseWarrants4Member 2017-06-30 0001314052 avxl:PurchaseWarrants5Member 2017-06-30 0001314052 avxl:PurchaseWarrants6Member 2017-06-30 0001314052 avxl:StockOptionPlan2015Member 2016-10-01 2017-06-30 0001314052 avxl:StockOptionPlan2015Member 2016-09-30 0001314052 avxl:StockOptionPlan2015Member 2017-06-30 0001314052 avxl:StockOptionPlan2015Member 2015-10-01 2016-09-30 0001314052 avxl:StockOptionPlan2015Member 2015-09-30 0001314052 us-gaap:EmployeeStockOptionMember 2017-06-30 0001314052 avxl:EmployeeStockOption1Member 2017-06-30 0001314052 avxl:EmployeeStockOption2Member 2017-06-30 0001314052 avxl:EmployeeStockOption3Member 2017-06-30 0001314052 avxl:EmployeeStockOption4Member 2017-06-30 0001314052 avxl:EmployeeStockOption5Member 2017-06-30 0001314052 avxl:EmployeeStockOption6Member 2017-06-30 0001314052 avxl:EmployeeStockOption7Member 2017-06-30 0001314052 avxl:EmployeeStockOption8Member 2017-06-30 0001314052 avxl:EmployeeStockOption9Member 2017-06-30 0001314052 avxl:EmployeeStockOption10Member 2017-06-30 0001314052 avxl:EmployeeStockOption11Member 2017-06-30 0001314052 avxl:EmployeeStockOption12Member 2017-06-30 0001314052 avxl:EmployeeStockOption13Member 2017-06-30 0001314052 avxl:EmployeeStockOption14Member 2017-06-30 0001314052 avxl:EmployeeStockOption15Member 2017-06-30 0001314052 avxl:EmployeeStockOption16Member 2017-06-30 0001314052 avxl:EmployeeStockOption17Member 2017-06-30 0001314052 avxl:EmployeeStockOption18Member 2017-06-30 0001314052 avxl:EmployeeStockOption19Member 2017-06-30 0001314052 avxl:EmployeeStockOption20Member 2017-06-30 0001314052 avxl:EmployeeStockOption21Member 2017-06-30 0001314052 avxl:EmployeeStockOption22Member 2017-06-30 0001314052 us-gaap:EmployeeStockOptionMember 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption1Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption2Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption3Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption4Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption5Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption6Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption7Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption8Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption9Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption10Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption11Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption12Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption13Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption14Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption15Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption16Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption17Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption18Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption19Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption20Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption21Member 2016-10-01 2017-06-30 0001314052 avxl:EmployeeStockOption22Member 2016-10-01 2017-06-30 0001314052 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001314052 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001314052 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001314052 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001314052 us-gaap:GeneralAndAdministrativeExpenseMember 2016-10-01 2017-06-30 0001314052 us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-06-30 0001314052 us-gaap:ResearchAndDevelopmentExpenseMember 2016-10-01 2017-06-30 0001314052 us-gaap:ResearchAndDevelopmentExpenseMember 2015-10-01 2016-06-30 0001314052 2016-09-30 0001314052 2015-09-30 0001314052 2016-06-30 0001314052 us-gaap:CommonStockMember 2016-10-01 2017-06-30 0001314052 us-gaap:CommonStockMember 2016-09-30 0001314052 us-gaap:CommonStockMember 2017-06-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2016-10-01 2017-06-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001314052 us-gaap:RetainedEarningsMember 2016-10-01 2017-06-30 0001314052 us-gaap:RetainedEarningsMember 2016-09-30 0001314052 us-gaap:RetainedEarningsMember 2017-06-30 0001314052 2017-08-07 0001314052 avxl:EmployeeStockOption23Member 2017-06-30 0001314052 avxl:EmployeeStockOption23Member 2016-10-01 2017-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ANAVEX LIFE SCIENCES CORP. 0001314052 10-Q 2017-06-30 false --09-30 No No Yes Accelerated Filer Q3 2017 AVXL

6746964

6008309

286455 121116 69146 47767 113701 2022902 571093 50000000 P36M

179598

5951229

89799

41195

59264

1609309 1262180 30000 277127 1252 31250 7500 3.00 4.00 1.20 1.68 1.24 1.04

2018-07-05

2019-02-24

2019-03-13

2019-05-31

2023-07-05

2024-05-07

2024-05-08

2025-04-02

2025-06-08

2025-06-15

2025-09-18

2025-09-30

2025-10-02

2025-10-16

2025-12-31

2026-03-31

2026-04-27

2026-05-18

2026-06-30

2026-07-05

2026-07-18

2026-09-07

2026-09-22

2026-10-03

2026-12-09

2027-02-07

2027-02-17

2027-05-12

4199000

5137655

1822500

500000

75000

125000

718750

29167

50000

273542

1500

31250

25000

1500

19697

1500

379625

861429

40000

1006696

89999

15000

50000

40000

800000

1080000

2401500

25000

2290717

3124885

3.76

4.13

2.00

1.6

1.20

1.32

0.92

1.44

1.76

5.04

5.64

5.68

8.98

5.57

4.9

5.66

4.09

6.11

6.26

7.06

3.06

3.28

3.63

4.35

5.39

5.26

5.92

5.55

5.22

14.68

2.41

2.89

5.48

4.38

3124885

500000

75000

93750

718750

29167

33333

177500

1500

18230

14583

1500

19697

1500

94906

215357

13333

1006696

29999

3750

6666

66668

8537225

1860000

309000

500000

3162500

113168

178000

76592

630

24227

90400

2053660

152098

14550

2400

P6Y4D

P6Y10M6D

P6Y10M10D

P7Y9M4D

P7Y11M8D

P7Y11M16D

P8Y2M19D

P8Y3M

P8Y3M4D

P8Y3M18D

P8Y6M

P8Y9M

P8Y9M25D

P8Y10M17D

P9Y

P9Y4D

P9Y0M18D

P9Y2M8D

P9Y2M23D

P9Y3M4D

P9Y5M8D

P9Y7M10D

P9Y7M17D

P9Y10M10D

2.66 2018-07-05

6050553

The Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Companys common stock exceeds $6.00 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements.

200000

52562

The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date.

P10Y

23452159

6308156

36169

42173

84290140

109733970

-78018153

-86323984

100000000

0.001

42172090

36168299

42172090

36168299

42172090

-8305831

-3610085

-2240356

-8225666

-8305831

42172090 610000

The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park’s committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.

5910939 22431958 40290 26210241

28047

112189

56094

196330

4272890

1809309

1609309

-2463581 -200000 2.11 2.70 2.66 1.67 3.00

141345

4.02

3017876

1159716

230239

1276967

574470

127473

585246

102766

1452181

715991

1565695

560976

8872029

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="text-align: justify; vertical-align: top"> <td style="text-align: left; width: 0.5in">Note 6</td> <td style="text-align: justify; text-decoration: underline">Commitments</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">a)</td> <td>Lease Commitment</td></tr> </table>   The Company is committed to lease payments as follows:   <table cellspacing="0" cellpadding="0" style="width: 40%; border-collapse: collapse; font-size: 10pt; margin-left: 1.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left">Fiscal year ending September 30,</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 67%">2017</td> <td style="text-align: left; width: 2%"> </td> <td style="width: 2%"> </td> <td style="text-align: left; width: 2%">$</td> <td style="text-align: right; width: 25%">28,047</td> <td style="text-align: left; width: 2%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">2018</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">112,189</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left">2019</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">56,094</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">196,330</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td></tr> </table>    <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">b)</td> <td>Litigation</td></tr> </table>   The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">c)</td> <td>Share Purchase Warrants</td></tr> </table>   A summary of the status of Company’s outstanding share purchase warrants is presented below:    <table cellspacing="0" cellpadding="0" style="width: 50%; border-collapse: collapse; font-size: 10pt; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 53%">Balance, October 1, 2015</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 20%">4,272,890</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">2.11</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Exercised</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,463,581</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.67</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Balance, September 30, 2016</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,809,309</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2.70</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Exercised</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(200,000</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">3.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Balance,June 30, 2017</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,609,309</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.66</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   At June 30, 2017, the Company had share purchase warrants outstanding of 1,609,309, with a weighted average exercise price of $2.66 as follows:   <table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiry Date</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 24%">1,262,180</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 24%">3.00</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 46%">July 5, 2018</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">30,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">February 24, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">277,127</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.20</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">March 13, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,252</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.68</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">March 13, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">31,250</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.24</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">May 31, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.04</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">May 31, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,609,309</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   All of the warrants expiring on July 5, 2018 contain a contingent call provision whereby the Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Company’s common stock exceeds $6.00 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements.   During the nine months ended June 30, 2017, 200,000 share purchase warrants were cashless exercised, resulting in the issuance of 52,562 shares of common stock.    <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">d)</td> <td style="text-align: justify">Stock–based Compensation Plan</td></tr> </table>   2015 Stock Option Plan   On September 18, 2015, the Company’s board of directors approved a 2015 Omnibus Incentive Plan (the “2015 Plan”), which provides for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.   The maximum number of our common shares reserved for issue under the plan is 6,050,553 shares subject to adjustment in the event of a change of the Company’s capitalization. As a result of the adoption of the 2015 Plan, no further option awards will be granted under any previously existing stock option plan. Stock option awards previously granted under previously existing stock option plans remain outstanding in accordance with their terms.   The 2015 Plan is administered by the board of directors, except that it may, in its discretion, delegate such responsibility to a committee of such board. The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.   A summary of the status of Company’s outstanding stock purchase options is presented below:   <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Grant Date fair value</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 42%">Outstanding at October 1, 2015</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 16%">1,822,500</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 16%">2.00</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 16%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Granted</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,401,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.22</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.38</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Expired</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(25,000</td> <td style="border-bottom: black 1pt solid; text-align: left">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">14.68</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Outstanding at September 30, 2016</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">4,199,000</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3.76</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Granted</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,080,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.55</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.48</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Forfeited</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(141,345</td> <td style="border-bottom: black 1pt solid; text-align: left">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">4.02</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Outstanding at June 30, 2017</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">5,137,655</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4.13</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Exercisable at June 30, 2017</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">3,124,885</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.89</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Exercisable at September 30, 2016</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">2,290,717</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.41</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>     At June 30, 2017, the following stock options were outstanding:  <table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Aggregate</td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Intrinsic</td> <td> </td> <td colspan="2" style="text-align: center">Contractual</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Vested</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiry Date</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Value</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (yrs)</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 12%">500,000</td> <td style="text-align: left; width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 12%">500,000</td> <td style="text-align: left; width: 2%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">1.60</td> <td style="text-align: left; width: 2%"> </td> <td style="text-align: right; padding-left: 5.4pt; width: 24%">July 5, 2023</td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">1,860,000</td> <td style="text-align: left; width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 12%">6.01</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">75,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">75,000</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.20</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">May 7, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">309,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.85</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">125,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">93,750</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.32</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">May 8, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">500,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.86</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">718,750</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">718,750</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.92</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">April 2, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,162,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.76</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">29,167</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">29,167</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.44</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">June 8, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">113,168</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.94</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">33,333</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.76</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">June 15, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">178,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.96</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">273,542</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">177,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.04</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">September 18, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">76,592</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.22</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.64</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">September 30, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.25</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">31,250</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">18,230</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.68</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">October 2, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.26</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">25,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,583</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">8.98</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">October 16, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.30</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.57</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.90</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">March 31, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">630</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.75</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.66</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">April 27, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.82</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">19,697</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">19,697</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.09</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">May 18, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">24,227</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.88</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">6.11</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">June 30, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">379,625</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">94,906</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">6.26</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">July 5, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.01</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">861,429</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">215,357</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">7.06</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">July 18, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">40,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">13,333</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">3.06</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">September 7, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">90,400</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.19</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,006,696</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,006,696</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">3.28</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">September 22, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,053,660</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.23</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">89,999</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">29,999</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">3.63</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">October 3, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">152,098</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.26</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">15,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,750</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.35</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">December 9, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,550</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.44</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.39</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">February 7, 2027</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.61</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">40,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,666</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.26</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">February 17, 2027</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,400</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.63</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">800,000</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">66,668</td> <td style="text-align: left"> </td> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">5.92</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-bottom: 1pt; padding-left: 5.4pt">May 12, 2027</td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">9.86</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">5,137,655</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">3,124,885</td> <td style="text-align: left"> </td> <td style="text-align: left; padding-bottom: 2pt"> </td> <td style="text-align: right; padding-bottom: 2pt"> </td> <td style="text-align: left"> </td> <td style="padding-bottom: 2pt; padding-left: 5.4pt"> </td> <td> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">8,537,225</td> <td style="text-align: left"> </td> <td style="text-align: left; padding-bottom: 2pt"> </td> <td style="text-align: right; padding-bottom: 2pt"> </td> <td style="text-align: left"> </td></tr> </table>   The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company’s stock for the options that were in-the-money at June     The Company recognized stock based compensation expense of $1,159,716 and $3,017,876, respectively, during the three and nine months ended June 30, 2017 (2016: $230,239 and $666,967 respectively) in connection with the issuance and vesting of stock options in exchange for services, and $Nil and $Nil respectively (2016: $Nil and $610,000, respectively), in connection with the vesting of restricted stock in exchange for services. These amounts have been included in general and administrative expenses and research and development expenses on the Company’s statement of operations as follows:   <table cellspacing="0" cellpadding="0" style="width: 89%; border-collapse: collapse; font-size: 10pt; margin-left: 1in"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="5" style="text-align: center">Three months ended June 30,</td> <td> </td> <td colspan="5" style="text-align: center">Nine months ended June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 48%">General and administrative</td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">574,470</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">127,473</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">1,452,181</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">715,991</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">585,246</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">102,766</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,565,695</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">560,976</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2pt">Total share based compensation</td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,159,716</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">230,239</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3,017,876</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,276,967</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td></tr> </table>   An amount of approximately $8,872,029 in stock based compensation is expected to be recorded over the remaining term of such options through March 31, 2020.   The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:    <table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 64%">Risk-free interest rate</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 16%">1.98</td> <td style="text-align: left; width: 1%">%</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 16%">1.67</td> <td style="text-align: left; width: 1%">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected life of options (years)</td> <td style="text-align: left"> </td> <td style="text-align: right">6.82</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.63</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Annualized volatility</td> <td style="text-align: left"> </td> <td style="text-align: right">111.67</td> <td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: right">105.21</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Dividend rate</td> <td style="text-align: left"> </td> <td style="text-align: right">0.00</td> <td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: right">0.00</td> <td style="text-align: left">%</td></tr> </table>    The fair value of restricted stock compensation charges during the nine months ended June 30, 2016 was determined with reference to the quoted market price of the Company’s shares on the commitment date.

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font-size: 10pt; margin-bottom: 0px"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">Note 7</td> <td style="text-decoration: underline">Comparative Figures</td></tr> </table>   Certain comparative figures have been reclassified to conform to the current year’s presentation.

Recent Accounting Pronouncements Adopted During the Period   In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on its financial condition, results of operations and cash flows.   In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on its financial condition, results of operations and cash flows.   In April 2015, the Financial Accounting Standards Board (FASB), issued the Accounting Standards Update 2015-03, Interest - Imputation of Interest (Subtopic 835-30) - Simplifying the Presentation of Debt Issuance Costs, that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. Upon adoption, an entity must apply the new guidance retrospectively to all prior periods presented in the financial statements. The Company adopted this standard on October 1, 2016. The adoption of this standard did not have any effect on its financial condition, results of operations and cash flows.   Recent Accounting Pronouncements Not Yet Adopted   In May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The adoption of this standard is not expected to have a material impact for any period presented.   In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-17 “Income Taxes: Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”). ASU 2015-17 eliminates the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. The adoption of this standard is not expected to have a material impact for any period presented.   In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (“ASU 2016-02”). The guidance would require lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right –of use assets. The guidance is effective for annual and interim reporting periods beginning on or after December 15, 2018. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.   In March 2016, the FASB issued ASC 2016-09, “Compensation – Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). These amendments are intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. These amendments are effective for the Company on October 1, 2017. Early adoption is permitted. Entities have the option to apply the amendments on either a prospective basis or a modified retrospective basis. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.   In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 reduces the existing diversity in practice in financial reporting across all industries by clarifying certain existing principles in ASC 230, Statement of Cash Flows, (“ASC 230”) including providing additional guidance on how and what an entity should consider in determining the classification of certain cash flows. In addition, in November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash (“ASU 2016-18”). ASU 2016-18 clarifies certain existing principles in ASC 230, including providing additional guidance related to transfers between cash and restricted cash and how entities present, in their statement of cash flows, the cash receipts and cash payments that directly affect the restricted cash accounts. These amendments are effective for annual and interim reporting periods beginning on or after December 15, 2017. Early adoption is permitted. The adoption of ASU 2016-15 and ASU 2016-18 will modify the Company’s current disclosures and reclassifications within the consolidated statement of cash flows but they are not expected to have a material effect on the Company’s consolidated financial statements.   In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting,” clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for the Company on a prospective basis beginning on October 1, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.   Other than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

The Company is committed to lease payments as follows:   <table cellspacing="0" cellpadding="0" style="width: 40%; border-collapse: collapse; font-size: 10pt; margin-left: 1.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left">Fiscal year ending September 30,</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 67%">2017</td> <td style="text-align: left; width: 2%"> </td> <td style="width: 2%"> </td> <td style="text-align: left; width: 2%">$</td> <td style="text-align: right; width: 25%">28,047</td> <td style="text-align: left; width: 2%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">2018</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">112,189</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left">2019</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">56,094</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">196,330</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td></tr> </table>

A summary of the status of Company’s outstanding share purchase warrants is presented below:    <table cellspacing="0" cellpadding="0" style="width: 50%; border-collapse: collapse; font-size: 10pt; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 53%">Balance, October 1, 2015</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 20%">4,272,890</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">2.11</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Exercised</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,463,581</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.67</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Balance, September 30, 2016</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,809,309</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2.70</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Exercised</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(200,000</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">3.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Balance,June 30, 2017</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,609,309</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.66</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

At June 30, 2017, the Company had share purchase warrants outstanding of 1,609,309, with a weighted average exercise price of $2.66 as follows:   <table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiry Date</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 24%">1,262,180</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 24%">3.00</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 46%">July 5, 2018</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">30,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">February 24, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">277,127</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.20</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">March 13, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,252</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.68</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">March 13, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">31,250</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.24</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">May 31, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.04</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">May 31, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,609,309</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the status of Company’s outstanding stock purchase options is presented below:   <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Grant Date fair value</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 42%">Outstanding at October 1, 2015</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 16%">1,822,500</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 16%">2.00</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 16%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Granted</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,401,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.22</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.38</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Expired</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(25,000</td> <td style="border-bottom: black 1pt solid; text-align: left">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">14.68</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Outstanding at September 30, 2016</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">4,199,000</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3.76</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Granted</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,080,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.55</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.48</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Forfeited</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(141,345</td> <td style="border-bottom: black 1pt solid; text-align: left">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">4.02</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Outstanding at June 30, 2017</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">5,137,655</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4.13</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Exercisable at June 30, 2017</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">3,124,885</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.89</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Exercisable at September 30, 2016</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">2,290,717</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.41</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

At June 30, 2017, the following stock options were outstanding:   <table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Aggregate</td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Intrinsic</td> <td> </td> <td colspan="2" style="text-align: center">Contractual</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Vested</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiry Date</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Value</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (yrs)</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 12%">500,000</td> <td style="text-align: left; width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 12%">500,000</td> <td style="text-align: left; width: 2%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">1.60</td> <td style="text-align: left; width: 2%"> </td> <td style="text-align: right; padding-left: 5.4pt; width: 24%">July 5, 2023</td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">1,860,000</td> <td style="text-align: left; width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 12%">6.01</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">75,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">75,000</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.20</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">May 7, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">309,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.85</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">125,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">93,750</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.32</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">May 8, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">500,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.86</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">718,750</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">718,750</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.92</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">April 2, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,162,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.76</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">29,167</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">29,167</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.44</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">June 8, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">113,168</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.94</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">33,333</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.76</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">June 15, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">178,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.96</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">273,542</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">177,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.04</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">September 18, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">76,592</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.22</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.64</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">September 30, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.25</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">31,250</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">18,230</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.68</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">October 2, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.26</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">25,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,583</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">8.98</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">October 16, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.30</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.57</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.90</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">March 31, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">630</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.75</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.66</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">April 27, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.82</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">19,697</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">19,697</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.09</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">May 18, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">24,227</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.88</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">6.11</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">June 30, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">379,625</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">94,906</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">6.26</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">July 5, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.01</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">861,429</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">215,357</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">7.06</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">July 18, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">40,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">13,333</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">3.06</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">September 7, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">90,400</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.19</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,006,696</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,006,696</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">3.28</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">September 22, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,053,660</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.23</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">89,999</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">29,999</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">3.63</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">October 3, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">152,098</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.26</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">15,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,750</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.35</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">December 9, 2026</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,550</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.44</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.39</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">February 7, 2027</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.61</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">40,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,666</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.26</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-left: 5.4pt">February 17, 2027</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,400</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.63</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">800,000</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">66,668</td> <td style="text-align: left"> </td> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">5.92</td> <td style="text-align: left"> </td> <td style="text-align: right; padding-bottom: 1pt; padding-left: 5.4pt">May 12, 2027</td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="text-align: left"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">9.86</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">5,137,655</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">3,124,885</td> <td style="text-align: left"> </td> <td style="text-align: left; padding-bottom: 2pt"> </td> <td style="text-align: right; padding-bottom: 2pt"> </td> <td style="text-align: left"> </td> <td style="padding-bottom: 2pt; padding-left: 5.4pt"> </td> <td> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">8,537,225</td> <td style="text-align: left"> </td> <td style="text-align: left; padding-bottom: 2pt"> </td> <td style="text-align: right; padding-bottom: 2pt"> </td> <td style="text-align: left"> </td></tr> </table>

These amounts have been included in general and administrative expenses and research and development expenses on the Company’s statement of operations as follows:   <table cellspacing="0" cellpadding="0" style="width: 89%; border-collapse: collapse; font-size: 10pt; margin-left: 1in"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="5" style="text-align: center">Three months ended June 30,</td> <td> </td> <td colspan="5" style="text-align: center">Nine months ended June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 48%">General and administrative</td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">574,470</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">127,473</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">1,452,181</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">715,991</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">585,246</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">102,766</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,565,695</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">560,976</td> <td style="border-bottom: black 1pt solid; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2pt">Total share based compensation</td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,159,716</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">230,239</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3,017,876</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,276,967</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td></tr> </table>

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:    <table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 64%">Risk-free interest rate</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 16%">1.98</td> <td style="text-align: left; width: 1%">%</td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 16%">1.67</td> <td style="text-align: left; width: 1%">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected life of options (years)</td> <td style="text-align: left"> </td> <td style="text-align: right">6.82</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.63</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Annualized volatility</td> <td style="text-align: left"> </td> <td style="text-align: right">111.67</td> <td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: right">105.21</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Dividend rate</td> <td style="text-align: left"> </td> <td style="text-align: right">0.00</td> <td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: right">0.00</td> <td style="text-align: left">%</td></tr> </table>

24906730

9498681

-86323984

-78018153

109733970

84290140

42173

36169

1454571

3190525

19073 70532

1435498

3119993

24906730

9498681

52396

24854334

9446285

52694

180124

8216 79347

40344149

41509225

35709686

34961838

-0.21

-0.09

-0.06

-0.24

50480

9877

6000

23615

-8255351

-3600208

-2234356

-8202051

2227573

105095

59309

804216

-40128

-65932

8924

-37637

1175

75204 75204 151402

48479

26677

2626

6832

2022902 571093

10482924

3705303

2293665

9006267

6835700

2300277

1158820

3888676

3647224

1405026

1134845

5117591

24793424

9186814

15290976

9727040

15606610

-5563936

22431958

1809620

-22431958

-1809620

-6825348

-7373556

-51459 -44490

-1594127

-294793

-127430

-32371

-55967

-28887

-2649

3017876

1276967

1175

746

3017876

52562 53 -53 40290 40 -40

5910939

22431958

5911

22426047

0.0198

0.0167

P6Y9M25D

P6Y7M17D

1.1167

1.0521

0.0000

EX-101.SCH 6 avxl-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Description and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Other Income link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Lincoln Park Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Comparative Figures link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Recent Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Business Description and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Other Income (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Lincoln Park Purchase Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Commitments (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Commitments (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Commitments (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Commitments (Details 5) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Commitments (Details 6) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 avxl-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 avxl-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 avxl-20170630_lab.xml XBRL LABEL FILE Type of Arrangement and Non-arrangement Transactions [Axis] Research & Development Incentive Program (Australian Government) [Member] 2015 Purchase Agreement [Member] Legal Entity [Axis] Lincoln Park Capital Fund, LLC [Member] Related Party [Axis] Directors and Officers [Member] Award Type [Axis] Purchase Warrants [Member] First Purchase Warrants [Member] Second Purchase Warrants [Member] Third Purchase Warrants [Member] Four Purchase Warrants [Member] Five Purchase Warrants [Member] Six Purchase Warrants [Member] Plan Name [Axis] 2015 Omnibus Incentive Plan [Member] First Stock Option [Member] Second Stock Option [Member] Third Stock Option [Member] Four Stock Option [Member] Five Stock Option [Member] Six Stock Option [Member] Seven Stock Option [Member] Eight Stock Option [Member] Nine Stock Option [Member] Ten Stock Option [Member] Eleven Stock Option [Member] Twelve Stock Option [Member] Thirteen Stock Option [Member] Fourteen Stock Option [Member] Fifteen Stock Option [Member] Sixteen Stock Option [Member] Seventeen Stock Option [Member] Eighteen Stock Option [Member] Nineteen Stock Option [Member] Twenty Stock Option [Member] Twenty One Stock Option [Member] Twenty Two Stock Option [Member] Twenty Three Stock Option [Member] Income Statement Location [Axis] General and administrative [Member] Research and development [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Twenty Four Stock Option [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Cash and cash equivalents Sales tax recoverable Prepaid expenses Current assets Deposits Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Accounts payable and accrued liabilities Deferred grant income Current liabilities Commitments - Note 6 Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 42,172,090 common shares (September 30, 2016 - 36,168,299) Additional paid-in capital Accumulated deficit Stockholders' equity Total liabilities and stockholder's equity Common shares, authorized Common shares, par value (in dollars per share) Common shares, issued Common shares, outstanding Income Statement [Abstract] Operating expenses General and administrative Research and development Total operating expenses Other income (expenses) Grant income Research and development incentive income Interest income, net Gain on settlement of accounts payable Financing related charges and adjustments Foreign exchange gain (loss) Total other income, net Net loss before provision for income taxes Income tax expense - current Net loss and comprehensive loss Loss per share Basic and diluted (in dollars per share) Weighted average number of shares outstanding Basic and diluted (in shares) Statement of Cash Flows [Abstract] Cash Flows used in Operating Activities Net loss Adjustments to reconcile net loss to net cash used in operations: Amortization and depreciation Accretion of debt discount Stock-based compensation Gain on settlement of accounts payable Unrealized foreign exchange Changes in non-cash working capital balances related to operations: Sales tax recoverable Prepaid expenses and deposits Accounts payable and accrued liabilities Deferred grant income Net cash used in operating activities Cash Flows provided by Financing Activity Issuance of common shares, net of share issue costs Net cash provided by financing activity Increase (decrease) in cash during the period Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Statement [Table] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Beginning Balance Beginning (in shares) Shares issued under purchase agreement - purchase shares Shares issued under purchase agreement - purchase shares (in shares) Shares issued under purchase agreement - commitment shares Shares issued under purchase agreement - commitment shares (in shares) Shares issued upon exercise of warrants - cashless Shares issued upon exercise of warrants - cashless (in shares) Share based compensation Net loss for the period Balance Ending Balance Ending (in shares) Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Description and Basis of Presentation New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Recent Accounting Pronouncements Deferred Revenue Disclosure [Abstract] Other Income Business Combinations [Abstract] Lincoln Park Purchase Agreement Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments Comparative Figures Comparative Figures Recent Accounting Pronouncements Schedule of lease payments Schedule of purchase warrants outstanding Schedule of exercisable share purchase warrants outstanding Schedule of outstanding stock purchase options Schedule of stock options outstanding Schedule of general and administrative expenses and research and development expenses Schedule of weighted average assumptions for fair value of each option award Loss per share for potentially dilutive common shares Awarded grant funding amount Total number of shares obligated to purchase Agreement term Description of purchases price Number of shares issued Pro rata basic number of shares obligated to purchase Number of shares issued for aggregate purchase price Number of shares issued for aggregate purchase price, value Number of shares issued for commitment Amount of shares remain available Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Accounts payable and accrued liabilities 2017 2018 2019 Operating leases, future minimum payments receivable Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Balance, at beginning Exercised Balance, at end Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward] Balance, at beginning Exercised Balance, at end Number Exercise Price EX-101.PRE 10 avxl-20170630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 07, 2017
Document And Entity Information
Entity Registrant Name	ANAVEX LIFE SCIENCES CORP.
Entity Central Index Key	0001314052
Document Type	10-Q
Trading Symbol	AVXL
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		42,172,090
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 12 R2.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Current
Cash and cash equivalents	$ 24,793,424	$ 9,186,814
Sales tax recoverable	8,216	79,347
Prepaid expenses	52,694	180,124
Current assets	24,854,334	9,446,285
Deposits	52,396	52,396
Total assets	24,906,730	9,498,681
Current
Accounts payable and accrued liabilities	1,435,498	3,119,993
Deferred grant income	19,073	70,532
Current liabilities	1,454,571	3,190,525
Commitments - Note 6
Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 42,172,090 common shares (September 30, 2016 - 36,168,299)	42,173	36,169
Additional paid-in capital	109,733,970	84,290,140
Accumulated deficit	(86,323,984)	(78,018,153)
Stockholders' equity	23,452,159	6,308,156
Total liabilities and stockholder's equity	$ 24,906,730	$ 9,498,681

XML 13 R3.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2017	Sep. 30, 2016
Statement of Financial Position [Abstract]
Common shares, authorized	100,000,000	100,000,000
Common shares, par value (in dollars per share)	$ 0.001	$ 0.001
Common shares, issued	42,172,090	36,168,299
Common shares, outstanding	42,172,090	36,168,299

XML 14 R4.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating expenses
General and administrative	$ 1,405,026	$ 1,134,845	$ 3,647,224	$ 5,117,591
Research and development	2,300,277	1,158,820	6,835,700	3,888,676
Total operating expenses	(3,705,303)	(2,293,665)	(10,482,924)	(9,006,267)
Other income (expenses)
Grant income	69,146	47,767	121,116	113,701
Research and development incentive income			2,022,902	571,093
Interest income, net	26,677	2,626	48,479	6,832
Gain on settlement of accounts payable	75,204		75,204	151,402
Financing related charges and adjustments		(8)		(1,175)
Foreign exchange gain (loss)	(65,932)	8,924	(40,128)	(37,637)
Total other income, net	105,095	59,309	2,227,573	804,216
Net loss before provision for income taxes	(3,600,208)	(2,234,356)	(8,255,351)	(8,202,051)
Income tax expense - current	(9,877)	(6,000)	(50,480)	(23,615)
Net loss and comprehensive loss	$ (3,610,085)	$ (2,240,356)	$ (8,305,831)	$ (8,225,666)
Loss per share
Basic and diluted (in dollars per share)	$ (0.09)	$ (0.06)	$ (0.21)	$ (0.24)
Weighted average number of shares outstanding
Basic and diluted (in shares)	41,509,225	35,709,686	40,344,149	34,961,838

XML 15 R5.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows used in Operating Activities
Net loss	$ (8,305,831)	$ (8,225,666)
Adjustments to reconcile net loss to net cash used in operations:
Amortization and depreciation		746
Accretion of debt discount		1,175
Stock-based compensation	3,017,876	1,276,967
Gain on settlement of accounts payable	(75,204)	(151,402)
Unrealized foreign exchange		2,649
Changes in non-cash working capital balances related to operations:
Sales tax recoverable	55,967	28,887
Prepaid expenses and deposits	127,430	32,371
Accounts payable and accrued liabilities	(1,594,127)	(294,793)
Deferred grant income	(51,459)	(44,490)
Net cash used in operating activities	(6,825,348)	(7,373,556)
Cash Flows provided by Financing Activity
Issuance of common shares, net of share issue costs	22,431,958	1,809,620
Net cash provided by financing activity	22,431,958	1,809,620
Increase (decrease) in cash during the period	15,606,610	(5,563,936)
Cash and cash equivalents, beginning of period	9,186,814	15,290,976
Cash and cash equivalents, end of period	$ 24,793,424	$ 9,727,040

XML 16 R6.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - 9 months ended Jun. 30, 2017 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance Beginning at Sep. 30, 2016	$ 36,169	$ 84,290,140	$ (78,018,153)	$ 6,308,156
Balance Beginning (in shares) at Sep. 30, 2016	36,168,299			36,168,299
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under purchase agreement - purchase shares	$ 5,911	22,426,047		$ 22,431,958
Shares issued under purchase agreement - purchase shares (in shares)	5,910,939
Shares issued under purchase agreement - commitment shares	$ 40	(40)
Shares issued under purchase agreement - commitment shares (in shares)	40,290
Shares issued upon exercise of warrants - cashless	$ 53	(53)
Shares issued upon exercise of warrants - cashless (in shares)	52,562
Share based compensation		3,017,876		3,017,876
Net loss for the period			(8,305,831)	(8,305,831)
Balance Ending at Jun. 30, 2017	$ 42,173	$ 109,733,970	$ (86,323,984)	$ 23,452,159
Balance Ending (in shares) at Jun. 30, 2017	42,172,090			42,172,090

XML 17 R7.htm IDEA: XBRL DOCUMENT

Business Description and Basis of Presentation

9 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description and Basis of Presentation

Note 1

Business Description and Basis of Presentation

Business

Basis of Presentation

Operating results for the nine months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2017.

Cash and cash equivalents

The Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to be cash equivalents.

Research and Development Incentive Income

Basic and Diluted Loss per Share

XML 18 R8.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Jun. 30, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recent Accounting Pronouncements

Note 2

Recent Accounting Pronouncements

Recent Accounting Pronouncements Adopted During the Period

Recent Accounting Pronouncements Not Yet Adopted

XML 19 R9.htm IDEA: XBRL DOCUMENT

Other Income

9 Months Ended

Jun. 30, 2017

Deferred Revenue Disclosure [Abstract]

Other Income

Note 3

Other Income

Deferred Grant Income

Research and development tax incentive

XML 20 R10.htm IDEA: XBRL DOCUMENT

Lincoln Park Purchase Agreement

9 Months Ended

Jun. 30, 2017

Business Combinations [Abstract]

Lincoln Park Purchase Agreement

Note 4

Lincoln Park Purchase Agreement

XML 21 R11.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Jun. 30, 2017

Related Party Transactions

Note 5

Related Party Transactions

XML 22 R12.htm IDEA: XBRL DOCUMENT

Commitments

9 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments

Note 6

Commitments

Lease Commitment

The Company is committed to lease payments as follows:

Fiscal year ending September 30,
2017	$	28,047
2018		112,189
2019		56,094
	$	196,330

Litigation

Share Purchase Warrants

A summary of the status of Company’s outstanding share purchase warrants is presented below:

	Number of Shares			Weighted Average Exercise Price
Balance, October 1, 2015		4,272,890		$	2.11
Exercised		(2,463,581	)	$	1.67
Balance, September 30, 2016		1,809,309		$	2.70
Exercised		(200,000	)	$	3.00
Balance,June 30, 2017		1,609,309		$	2.66

At June 30, 2017, the Company had share purchase warrants outstanding of 1,609,309, with a weighted average exercise price of $2.66 as follows:

Number		Exercise Price		Expiry Date
	1,262,180	$	3.00	July 5, 2018
	30,000	$	4.00	February 24, 2019
	277,127	$	1.20	March 13, 2019
	1,252	$	1.68	March 13, 2019
	31,250	$	1.24	May 31, 2019
	7,500	$	1.04	May 31, 2019
	1,609,309

During the nine months ended June 30, 2017, 200,000 share purchase warrants were cashless exercised, resulting in the issuance of 52,562 shares of common stock.

Stock–based Compensation Plan

2015 Stock Option Plan

A summary of the status of Company’s outstanding stock purchase options is presented below:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Grant Date fair value
Outstanding at October 1, 2015		1,822,500		$	2.00
Granted		2,401,500		$	5.22	$	4.38
Expired		(25,000	)	$	14.68
Outstanding at September 30, 2016		4,199,000		$	3.76
Granted		1,080,000		$	5.55	$	5.48
Forfeited		(141,345	)	$	4.02
Outstanding at June 30, 2017		5,137,655		$	4.13
Exercisable at June 30, 2017		3,124,885		$	2.89
Exercisable at September 30, 2016		2,290,717		$	2.41

At June 30, 2017, the following stock options were outstanding:


Number of Shares							Aggregate		Remaining
		Number		Exercise			Intrinsic		Contractual
Total		Vested		Price		Expiry Date	Value		Life (yrs)
	500,000		500,000	$	1.60	July 5, 2023	$	1,860,000		6.01
	75,000		75,000	$	1.20	May 7, 2024		309,000		6.85
	125,000		93,750	$	1.32	May 8, 2024		500,000		6.86
	718,750		718,750	$	0.92	April 2, 2025		3,162,500		7.76
	29,167		29,167	$	1.44	June 8, 2025		113,168		7.94
	50,000		33,333	$	1.76	June 15, 2025		178,000		7.96
	273,542		177,500	$	5.04	September 18, 2025		76,592		8.22
	1,500		1,500	$	5.64	September 30, 2025		—		8.25
	31,250		18,230	$	5.68	October 2, 2025		—		8.26
	25,000		14,583	$	8.98	October 16, 2025		—		8.30
	1,500		1,500	$	5.57	December 31, 2025		—		8.50
	1,500		1,500	$	4.90	March 31, 2026		630		8.75
	1,500		1,500	$	5.66	April 27, 2026		—		8.82
	19,697		19,697	$	4.09	May 18, 2026		24,227		8.88
	1,500		1,500	$	6.11	June 30, 2026		—		9.00
	379,625		94,906	$	6.26	July 5, 2026		—		9.01
	861,429		215,357	$	7.06	July 18, 2026		—		9.05
	40,000		13,333	$	3.06	September 7, 2026		90,400		9.19
	1,006,696		1,006,696	$	3.28	September 22, 2026		2,053,660		9.23
	89,999		29,999	$	3.63	October 3, 2026		152,098		9.26
	15,000		3,750	$	4.35	December 9, 2026		14,550		9.44
	50,000		—	$	5.39	February 7, 2027		—		9.61
	40,000		6,666	$	5.26	February 17, 2027		2,400		9.63
	800,000		66,668	$	5.92	May 12, 2027		—		9.86
	5,137,655		3,124,885				$	8,537,225

	Three months ended June 30,				Nine months ended June 30,
	2017		2016		2017		2016
General and administrative	$	574,470	$	127,473	$	1,452,181	$	715,991
Research and development		585,246		102,766		1,565,695		560,976
Total share based compensation	$	1,159,716	$	230,239	$	3,017,876	$	1,276,967

An amount of approximately $8,872,029 in stock based compensation is expected to be recorded over the remaining term of such options through March 31, 2020.

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:

	2017			2016
Risk-free interest rate		1.98	%		1.67	%
Expected life of options (years)		6.82			6.63
Annualized volatility		111.67	%		105.21	%
Dividend rate		0.00	%		0.00	%

XML 23 R13.htm IDEA: XBRL DOCUMENT

Comparative Figures

9 Months Ended

Jun. 30, 2017

Comparative Figures

Comparative Figures

Note 7

Comparative Figures

Certain comparative figures have been reclassified to conform to the current year’s presentation.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements (Policies)

9 Months Ended

Jun. 30, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recent Accounting Pronouncements

Recent Accounting Pronouncements Adopted During the Period

Recent Accounting Pronouncements Not Yet Adopted

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of lease payments

The Company is committed to lease payments as follows:

Fiscal year ending September 30,
2017	$	28,047
2018		112,189
2019		56,094
	$	196,330

Schedule of purchase warrants outstanding

A summary of the status of Company’s outstanding share purchase warrants is presented below:

	Number of Shares			Weighted Average Exercise Price
Balance, October 1, 2015		4,272,890		$	2.11
Exercised		(2,463,581	)	$	1.67
Balance, September 30, 2016		1,809,309		$	2.70
Exercised		(200,000	)	$	3.00
Balance,June 30, 2017		1,609,309		$	2.66

Schedule of exercisable share purchase warrants outstanding

At June 30, 2017, the Company had share purchase warrants outstanding of 1,609,309, with a weighted average exercise price of $2.66 as follows:

Number		Exercise Price		Expiry Date
	1,262,180	$	3.00	July 5, 2018
	30,000	$	4.00	February 24, 2019
	277,127	$	1.20	March 13, 2019
	1,252	$	1.68	March 13, 2019
	31,250	$	1.24	May 31, 2019
	7,500	$	1.04	May 31, 2019
	1,609,309

Schedule of outstanding stock purchase options

A summary of the status of Company’s outstanding stock purchase options is presented below:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Grant Date fair value
Outstanding at October 1, 2015		1,822,500		$	2.00
Granted		2,401,500		$	5.22	$	4.38
Expired		(25,000	)	$	14.68
Outstanding at September 30, 2016		4,199,000		$	3.76
Granted		1,080,000		$	5.55	$	5.48
Forfeited		(141,345	)	$	4.02
Outstanding at June 30, 2017		5,137,655		$	4.13
Exercisable at June 30, 2017		3,124,885		$	2.89
Exercisable at September 30, 2016		2,290,717		$	2.41

Schedule of stock options outstanding

At June 30, 2017, the following stock options were outstanding:

Number of Shares							Aggregate		Remaining
		Number		Exercise			Intrinsic		Contractual
Total		Vested		Price		Expiry Date	Value		Life (yrs)
	500,000		500,000	$	1.60	July 5, 2023	$	1,860,000		6.01
	75,000		75,000	$	1.20	May 7, 2024		309,000		6.85
	125,000		93,750	$	1.32	May 8, 2024		500,000		6.86
	718,750		718,750	$	0.92	April 2, 2025		3,162,500		7.76
	29,167		29,167	$	1.44	June 8, 2025		113,168		7.94
	50,000		33,333	$	1.76	June 15, 2025		178,000		7.96
	273,542		177,500	$	5.04	September 18, 2025		76,592		8.22
	1,500		1,500	$	5.64	September 30, 2025		—		8.25
	31,250		18,230	$	5.68	October 2, 2025		—		8.26
	25,000		14,583	$	8.98	October 16, 2025		—		8.30
	1,500		1,500	$	5.57	December 31, 2025		—		8.50
	1,500		1,500	$	4.90	March 31, 2026		630		8.75
	1,500		1,500	$	5.66	April 27, 2026		—		8.82
	19,697		19,697	$	4.09	May 18, 2026		24,227		8.88
	1,500		1,500	$	6.11	June 30, 2026		—		9.00
	379,625		94,906	$	6.26	July 5, 2026		—		9.01
	861,429		215,357	$	7.06	July 18, 2026		—		9.05
	40,000		13,333	$	3.06	September 7, 2026		90,400		9.19
	1,006,696		1,006,696	$	3.28	September 22, 2026		2,053,660		9.23
	89,999		29,999	$	3.63	October 3, 2026		152,098		9.26
	15,000		3,750	$	4.35	December 9, 2026		14,550		9.44
	50,000		—	$	5.39	February 7, 2027		—		9.61
	40,000		6,666	$	5.26	February 17, 2027		2,400		9.63
	800,000		66,668	$	5.92	May 12, 2027		—		9.86
	5,137,655		3,124,885				$	8,537,225

Schedule of general and administrative expenses and research and development expenses

These amounts have been included in general and administrative expenses and research and development expenses on the Company’s statement of operations as follows:

	Three months ended June 30,				Nine months ended June 30,
	2017		2016		2017		2016
General and administrative	$	574,470	$	127,473	$	1,452,181	$	715,991
Research and development		585,246		102,766		1,565,695		560,976
Total share based compensation	$	1,159,716	$	230,239	$	3,017,876	$	1,276,967

Schedule of weighted average assumptions for fair value of each option award

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:

	2017			2016
Risk-free interest rate		1.98	%		1.67	%
Expected life of options (years)		6.82			6.63
Annualized volatility		111.67	%		105.21	%
Dividend rate		0.00	%		0.00	%

XML 26 R16.htm IDEA: XBRL DOCUMENT

Business Description and Basis of Presentation (Details Narrative) - shares	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Loss per share for potentially dilutive common shares	6,746,964	6,008,309

XML 27 R17.htm IDEA: XBRL DOCUMENT

Other Income (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
Other Income (Details Narrative) - USD ($)	Jun. 19, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Awarded grant funding amount	$ 286,455
Grant income		$ 69,146	$ 47,767	$ 121,116	$ 113,701
Research & Development Incentive Program (Australian Government) [Member]
Grant income				$ 2,022,902	$ 571,093

XML 28 R18.htm IDEA: XBRL DOCUMENT

Lincoln Park Purchase Agreement (Details Narrative) - 2015 Purchase Agreement [Member] - Lincoln Park Capital Fund, LLC [Member] - USD ($)		9 Months Ended
	Oct. 21, 2015	Jun. 30, 2017
Total number of shares obligated to purchase	$ 50,000,000
Agreement term	36 months
Description of purchases price	The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park’s committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.
Number of shares issued	179,598	5,951,229
Pro rata basic number of shares obligated to purchase	89,799
Number of shares issued for aggregate purchase price		5,910,939
Number of shares issued for aggregate purchase price, value		$ 22,431,958
Number of shares issued for commitment		40,290
Amount of shares remain available		$ 26,210,241

XML 29 R19.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Directors and Officers [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities	$ 41,195	$ 59,264

XML 30 R20.htm IDEA: XBRL DOCUMENT

Commitments (Details)	Jun. 30, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2017	$ 28,047
2018	112,189
2019	56,094
Operating leases, future minimum payments receivable	$ 196,330

XML 31 R21.htm IDEA: XBRL DOCUMENT

Commitments (Details 1) - Purchase Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Balance, at beginning	1,809,309	4,272,890
Exercised	(200,000)	(2,463,581)
Balance, at end	1,609,309	1,809,309
Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]
Balance, at beginning	$ 2.70	$ 2.11
Exercised	3.00	1.67
Balance, at end	$ 2.66	$ 2.70

XML 32 R22.htm IDEA: XBRL DOCUMENT

Commitments (Details 2)	9 Months Ended
Commitments (Details 2)	Jun. 30, 2017 $ / shares shares
First Purchase Warrants [Member]
Number	1,262,180
Exercise Price \| $ / shares	$ 3.00
Expiry Date	Jul. 05, 2018
Second Purchase Warrants [Member]
Number	30,000
Exercise Price \| $ / shares	$ 4.00
Expiry Date	Feb. 24, 2019
Third Purchase Warrants [Member]
Number	277,127
Exercise Price \| $ / shares	$ 1.20
Expiry Date	Mar. 13, 2019
Four Purchase Warrants [Member]
Number	1,252
Exercise Price \| $ / shares	$ 1.68
Expiry Date	Mar. 13, 2019
Five Purchase Warrants [Member]
Number	31,250
Exercise Price \| $ / shares	$ 1.24
Expiry Date	May 31, 2019
Six Purchase Warrants [Member]
Number	7,500
Exercise Price \| $ / shares	$ 1.04
Expiry Date	May 31, 2019
Purchase Warrants [Member]
Number	1,609,309

XML 33 R23.htm IDEA: XBRL DOCUMENT

Commitments (Details 3) - 2015 Omnibus Incentive Plan [Member] - $ / shares	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning	4,199,000	1,822,500
Granted	1,080,000	2,401,500
Expired		(25,000)
Forfeited	(141,345)
Outstanding at ending	5,137,655	4,199,000
Exercisable at ending	3,124,885	2,290,717
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning	$ 3.76	$ 2.00
Granted	5.55	5.22
Expired		14.68
Forfeited	4.02
Outstanding at ending	4.13	3.76
Exercisable at ending	2.89	2.41
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Roll Forward]
Granted	$ 5.48	$ 4.38

XML 34 R24.htm IDEA: XBRL DOCUMENT

Commitments (Details 4) - USD ($)	9 Months Ended
Commitments (Details 4) - USD ($)	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
First Stock Option [Member]
Total Number of Shares	500,000
Number of Vested Shares	500,000
Exercise Price	$ 1.6
Expiry Date	Jul. 05, 2023
Aggregate Intrinsic Value	$ 1,860,000
Remaining Contractual Life (in years)	6 years 4 days
Second Stock Option [Member]
Total Number of Shares	75,000
Number of Vested Shares	75,000
Exercise Price	$ 1.20
Expiry Date	May 07, 2024
Aggregate Intrinsic Value	$ 309,000
Remaining Contractual Life (in years)	6 years 10 months 6 days
Third Stock Option [Member]
Total Number of Shares	125,000
Number of Vested Shares	93,750
Exercise Price	$ 1.32
Expiry Date	May 08, 2024
Aggregate Intrinsic Value	$ 500,000
Remaining Contractual Life (in years)	6 years 10 months 10 days
Four Stock Option [Member]
Total Number of Shares	718,750
Number of Vested Shares	718,750
Exercise Price	$ 0.92
Expiry Date	Apr. 02, 2025
Aggregate Intrinsic Value	$ 3,162,500
Remaining Contractual Life (in years)	7 years 9 months 4 days
Five Stock Option [Member]
Total Number of Shares	29,167
Number of Vested Shares	29,167
Exercise Price	$ 1.44
Expiry Date	Jun. 08, 2025
Aggregate Intrinsic Value	$ 113,168
Remaining Contractual Life (in years)	7 years 11 months 8 days
Six Stock Option [Member]
Total Number of Shares	50,000
Number of Vested Shares	33,333
Exercise Price	$ 1.76
Expiry Date	Jun. 15, 2025
Aggregate Intrinsic Value	$ 178,000
Remaining Contractual Life (in years)	7 years 11 months 16 days
Seven Stock Option [Member]
Total Number of Shares	273,542
Number of Vested Shares	177,500
Exercise Price	$ 5.04
Expiry Date	Sep. 18, 2025
Aggregate Intrinsic Value	$ 76,592
Remaining Contractual Life (in years)	8 years 2 months 19 days
Eight Stock Option [Member]
Total Number of Shares	1,500
Number of Vested Shares	1,500
Exercise Price	$ 5.64
Expiry Date	Sep. 30, 2025
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	8 years 3 months
Nine Stock Option [Member]
Total Number of Shares	31,250
Number of Vested Shares	18,230
Exercise Price	$ 5.68
Expiry Date	Oct. 02, 2025
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	8 years 3 months 4 days
Ten Stock Option [Member]
Total Number of Shares	25,000
Number of Vested Shares	14,583
Exercise Price	$ 8.98
Expiry Date	Oct. 16, 2025
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	8 years 3 months 18 days
Eleven Stock Option [Member]
Total Number of Shares	1,500
Number of Vested Shares	1,500
Exercise Price	$ 5.57
Expiry Date	Dec. 31, 2025
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	8 years 6 months
Twelve Stock Option [Member]
Total Number of Shares	1,500
Number of Vested Shares	1,500
Exercise Price	$ 4.9
Expiry Date	Mar. 31, 2026
Aggregate Intrinsic Value	$ 630
Remaining Contractual Life (in years)	8 years 9 months
Thirteen Stock Option [Member]
Total Number of Shares	1,500
Number of Vested Shares	1,500
Exercise Price	$ 5.66
Expiry Date	Apr. 27, 2026
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	8 years 9 months 25 days
Fourteen Stock Option [Member]
Total Number of Shares	19,697
Number of Vested Shares	19,697
Exercise Price	$ 4.09
Expiry Date	May 18, 2026
Aggregate Intrinsic Value	$ 24,227
Remaining Contractual Life (in years)	8 years 10 months 17 days
Fifteen Stock Option [Member]
Total Number of Shares	1,500
Number of Vested Shares	1,500
Exercise Price	$ 6.11
Expiry Date	Jun. 30, 2026
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	9 years
Sixteen Stock Option [Member]
Total Number of Shares	379,625
Number of Vested Shares	94,906
Exercise Price	$ 6.26
Expiry Date	Jul. 05, 2026
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	9 years 4 days
Seventeen Stock Option [Member]
Total Number of Shares	861,429
Number of Vested Shares	215,357
Exercise Price	$ 7.06
Expiry Date	Jul. 18, 2026
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	9 years 18 days
Eighteen Stock Option [Member]
Total Number of Shares	40,000
Number of Vested Shares	13,333
Exercise Price	$ 3.06
Expiry Date	Sep. 07, 2026
Aggregate Intrinsic Value	$ 90,400
Remaining Contractual Life (in years)	9 years 2 months 8 days
Nineteen Stock Option [Member]
Total Number of Shares	1,006,696
Number of Vested Shares	1,006,696
Exercise Price	$ 3.28
Expiry Date	Sep. 22, 2026
Aggregate Intrinsic Value	$ 2,053,660
Remaining Contractual Life (in years)	9 years 2 months 23 days
Twenty Stock Option [Member]
Total Number of Shares	89,999
Number of Vested Shares	29,999
Exercise Price	$ 3.63
Expiry Date	Oct. 03, 2026
Aggregate Intrinsic Value	$ 152,098
Remaining Contractual Life (in years)	9 years 3 months 4 days
Twenty One Stock Option [Member]
Total Number of Shares	15,000
Number of Vested Shares	3,750
Exercise Price	$ 4.35
Expiry Date	Dec. 09, 2026
Aggregate Intrinsic Value	$ 14,550
Remaining Contractual Life (in years)	9 years 5 months 8 days
Twenty Two Stock Option [Member]
Total Number of Shares	50,000
Number of Vested Shares
Exercise Price	$ 5.39
Expiry Date	Feb. 07, 2027
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	9 years 7 months 10 days
Twenty Three Stock Option [Member]
Total Number of Shares	40,000
Number of Vested Shares	6,666
Exercise Price	$ 5.26
Expiry Date	Feb. 17, 2027
Aggregate Intrinsic Value	$ 2,400
Remaining Contractual Life (in years)	9 years 7 months 17 days
Twenty Four Stock Option [Member]
Total Number of Shares	800,000
Number of Vested Shares	66,668
Exercise Price	$ 5.92
Expiry Date	May 12, 2027
Aggregate Intrinsic Value
Remaining Contractual Life (in years)	9 years 10 months 10 days
2015 Omnibus Incentive Plan [Member]
Total Number of Shares	5,137,655	4,199,000	1,822,500
Number of Vested Shares	3,124,885
Exercise Price	$ 4.13	$ 3.76	$ 2.00
Aggregate Intrinsic Value	$ 8,537,225

XML 35 R25.htm IDEA: XBRL DOCUMENT

Commitments (Details 5) - USD ($)	3 Months Ended		9 Months Ended
Commitments (Details 5) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Total share based compensation	$ 1,159,716	$ 230,239	$ 3,017,876	$ 1,276,967
General and administrative [Member]
Total share based compensation	574,470	127,473	1,452,181	715,991
Research and development [Member]
Total share based compensation	$ 585,246	$ 102,766	$ 1,565,695	$ 560,976

XML 36 R26.htm IDEA: XBRL DOCUMENT

Commitments (Details 6)	9 Months Ended
Commitments (Details 6)	Jun. 30, 2017	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Risk-free interest rate	1.98%	1.67%
Expected life of options (years)	6 years 9 months 25 days	6 years 7 months 17 days
Annualized volatility	111.67%	105.21%
Dividend rate	0.00%	0.00%

XML 37 R27.htm IDEA: XBRL DOCUMENT

Commitments (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Commitments (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Remaining stock based compensation			$ 8,872,029
Share based compensation	$ 1,159,716	$ 230,239	3,017,876	$ 1,276,967
Share based compensation with the vesting of restricted stock				$ 610,000
2015 Omnibus Incentive Plan [Member]
Maximum number of common shares reserved for future issuance	6,050,553		6,050,553
Description of grant option			The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date.
Expiration period			10 years
Purchase Warrants [Member]
Number of warrant exercisable	1,609,309		1,609,309
Weighted average exercise price	$ 2.66		$ 2.66
Expiration date			Jul. 05, 2018
Description of cancellation policy			The Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Company’s common stock exceeds $6.00 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements.
Number of warrants exercised	200,000		200,000
Number of common shares called	52,562		52,562

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 106 134 1 false 41 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://anavex.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 00000007 - Disclosure - Business Description and Basis of Presentation Sheet http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation Business Description and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Recent Accounting Pronouncements Sheet http://anavex.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 8 false false R9.htm 00000009 - Disclosure - Other Income Sheet http://anavex.com/role/OtherIncome Other Income Notes 9 false false R10.htm 00000010 - Disclosure - Lincoln Park Purchase Agreement Sheet http://anavex.com/role/LincolnParkPurchaseAgreement Lincoln Park Purchase Agreement Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://anavex.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Commitments Sheet http://anavex.com/role/Commitments Commitments Notes 12 false false R13.htm 00000013 - Disclosure - Comparative Figures Sheet http://anavex.com/role/ComparativeFigures Comparative Figures Notes 13 false false R14.htm 00000014 - Disclosure - Recent Accounting Pronouncements (Policies) Sheet http://anavex.com/role/RecentAccountingPronouncementsPolicies Recent Accounting Pronouncements (Policies) Policies http://anavex.com/role/RecentAccountingPronouncements 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies (Tables) Sheet http://anavex.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables 15 false false R16.htm 00000016 - Disclosure - Business Description and Basis of Presentation (Details Narrative) Sheet http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative Business Description and Basis of Presentation (Details Narrative) Details http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation 16 false false R17.htm 00000017 - Disclosure - Other Income (Details Narrative) Sheet http://anavex.com/role/OtherIncomeDetailsNarrative Other Income (Details Narrative) Details http://anavex.com/role/OtherIncome 17 false false R18.htm 00000018 - Disclosure - Lincoln Park Purchase Agreement (Details Narrative) Sheet http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative Lincoln Park Purchase Agreement (Details Narrative) Details http://anavex.com/role/LincolnParkPurchaseAgreement 18 false false R19.htm 00000019 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://anavex.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://anavex.com/role/RelatedPartyTransactions 19 false false R20.htm 00000020 - Disclosure - Commitments (Details) Sheet http://anavex.com/role/CommitmentsDetails Commitments (Details) Details http://anavex.com/role/CommitmentsAndContingenciesTables 20 false false R21.htm 00000021 - Disclosure - Commitments (Details 1) Sheet http://anavex.com/role/CommitmentsDetails1 Commitments (Details 1) Details http://anavex.com/role/CommitmentsAndContingenciesTables 21 false false R22.htm 00000022 - Disclosure - Commitments (Details 2) Sheet http://anavex.com/role/CommitmentsDetails2 Commitments (Details 2) Details http://anavex.com/role/CommitmentsAndContingenciesTables 22 false false R23.htm 00000023 - Disclosure - Commitments (Details 3) Sheet http://anavex.com/role/CommitmentsDetails3 Commitments (Details 3) Details http://anavex.com/role/CommitmentsAndContingenciesTables 23 false false R24.htm 00000024 - Disclosure - Commitments (Details 4) Sheet http://anavex.com/role/CommitmentsDetails4 Commitments (Details 4) Details http://anavex.com/role/CommitmentsAndContingenciesTables 24 false false R25.htm 00000025 - Disclosure - Commitments (Details 5) Sheet http://anavex.com/role/CommitmentsDetails5 Commitments (Details 5) Details http://anavex.com/role/CommitmentsAndContingenciesTables 25 false false R26.htm 00000026 - Disclosure - Commitments (Details 6) Sheet http://anavex.com/role/CommitmentsDetails6 Commitments (Details 6) Details http://anavex.com/role/CommitmentsAndContingenciesTables 26 false false R27.htm 00000027 - Disclosure - Commitments (Details Narrative) Sheet http://anavex.com/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://anavex.com/role/CommitmentsAndContingenciesTables 27 false false All Reports Book All Reports avxl-20170630.xml avxl-20170630.xsd avxl-20170630_cal.xml avxl-20170630_def.xml avxl-20170630_lab.xml avxl-20170630_pre.xml true true ZIP 44 0001615774-17-004118-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-17-004118-xbrl.zip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